

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055351
Article Type:	Protocol
Date Submitted by the Author:	09-Jul-2021
Complete List of Authors:	<p>Colomer-Carbonell, Ariadna; Institut de Recerca Sant Joan de Déu, Teaching, Research &amp; Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology</p> <p>Sanabria-Mazo, Juan; Institut de Recerca Sant Joan de Déu, Teaching, Research &amp; Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology</p> <p>Hernández-Negrín, Halbert; Universidad de Ciencias Médicas de Villa Clara</p> <p>Borràs, Xavier; Autonomous University of Barcelona,</p> <p>Suso-Ribera, Carlos; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology</p> <p>García-Palacios, Azucena; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology</p> <p>Muchart, Jordi; Hospital Sant Joan de Déu, Diagnostic Imaging Department</p> <p>Munuera, Josep; Hospital Sant Joan de Déu, Diagnostic Imaging Department</p> <p>D'Amico, Francesco; London School of Economics and Political Science, Personal Social Services Research Unit</p> <p>Maes, Michael; Chulalongkorn University, Department of Psychiatry</p> <p>Younger, Jarred; University of Alabama at Birmingham</p> <p>Feliu-Soler, Albert; Autonomous University of Barcelona, Department of Clinical and Health Psychology</p> <p>Rozadilla-Sacanell, Antoni; Institut de Recerca Sant Joan de Déu, Department of Rheumatology - Parc Sanitari Sant Joan de Déu</p> <p>Luciano, Juan; Institut de Recerca Sant Joan de Déu, Teaching, Research &amp; Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Clinical and Health Psychology</p>
Keywords:	PAIN MANAGEMENT, HEALTH ECONOMICS, Clinical trials < THERAPEUTICS



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open: first published as 10.1136/bmjopen-2021-055351 on 6 January 2022. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.

1  
2  
3 **Study protocol for a randomised, double-blinded, placebo-controlled phase III trial**  
4 **examining the add-on efficacy, cost-utility and neurobiological effects of low-dose**  
5 **naltrexone (LDN) in patients with fibromyalgia (INNOVA study)**  
6  
7  
8  
9

10  
11  
12 Ariadna Colomer-Carbonell<sup>1,2,3\*</sup>. ORCID: 0000-0001-8923-6316

13  
14 Juan P. Sanabria-Mazo<sup>1,2,3\*</sup>. ORCID: 0000-0003-1688-435X

15  
16 Halbert Hernández-Negrín<sup>4\*</sup>. ORCID: 0000-0002-9992-9148

17  
18 Xavier Borràs<sup>3</sup>. ORCID: 0000-0003-3972-1385

19  
20 Carlos Suso-Ribera<sup>5,6</sup>. ORCID: 0000-0002-2655-1017

21  
22 Azucena García-Palacios<sup>5,6</sup>. ORCID: 0000-0001-9250-8714

23  
24 Jordi Muchart<sup>7</sup>. ORCID: 0000-0003-4702-5072

25  
26 Josep Munuera<sup>7</sup>. ORCID: 0000-0001-5154-1796

27  
28 Francesco D'Amico<sup>8</sup>. ORCID: 0000-0001-5289-9300

29  
30 Michael Maes<sup>9</sup>. ORCID: 0000-0002-2012-871X

31  
32 Jarred W. Younger<sup>10</sup>. ORCID: 0000-0003-3616-9919

33  
34 Albert Feliu-Soler<sup>11\*\*</sup>. ORCID: 0000-0003-2810-7670

35  
36 Antoni Rozadilla-Sacanel<sup>1,12,13\*\*</sup>. ORCID: 0000-0002-7555-189X

37  
38 Juan V. Luciano<sup>1,2,11\*\*</sup>. ORCID: 0000-0003-0750-1599  
39  
40  
41  
42  
43  
44  
45  
46

47 **Author affiliations**

48  
49 <sup>1</sup>Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain

50  
51 <sup>2</sup>Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat,  
52 Spain  
53

54  
55 <sup>3</sup>Department of Basics, Developmental and Educational Psychology, Faculty of Psychology,  
56 Autonomous University of Barcelona, Cerdanyola del Vallès, Spain  
57  
58  
59  
60

1  
2  
3 <sup>4</sup>Hospital Universitario Arnaldo Milián Castro & Universidad de Ciencias Médicas de Villa  
4 Clara, Santa Clara, Cuba.

5  
6  
7  
8 <sup>5</sup>Department of Basic and Clinical Psychology and Psychobiology, University Jaume I,  
9 Castellon de la Plana, Spain

10  
11  
12 <sup>6</sup>Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn),  
13 Institute of Health Carlos III, Madrid, Spain

14  
15  
16  
17 <sup>7</sup>Diagnostic Imaging Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain

18  
19  
20 <sup>8</sup>Personal Social Services Research Unit, London School of Economics and Political Science,  
21 London, UK

22  
23  
24 <sup>9</sup>Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand

25  
26  
27 <sup>10</sup>Department of Psychology, University of Alabama at Birmingham, Birmingham, USA

28  
29  
30  
31 <sup>11</sup>Department of Clinical and Health Psychology, Faculty of Psychology, Autonomous  
32 University of Barcelona, Cerdanyola del Vallès, Spain

33  
34 <sup>12</sup> Rheumatology Service, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat, Spain

35  
36  
37 <sup>13</sup>School of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain

38  
39  
40  
41 \*AC-C, JPS-M and HH-N are joint first authors.

42  
43  
44 \*\*AF-S, AR-S and JVL are joint senior authors.

## 45 46 47 48 49 50 51 52 **Correspondence**

53  
54  
55 Juan V. Luciano, PhD. Teaching, Research & Innovation Unit - Parc Sanitari Sant Joan de Déu.  
56 C/ Dr. Antoni Pujadas, 42. 08830. St. Boi de Llobregat, Spain. E-mail:  
57 juanvicente.luciano@sjd.es  
58  
59  
60

## ABSTRACT

**Introduction.** There is evidence that low-dose naltrexone (LDN; < 5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility, and neurobiological effects of LDN for reducing pain in FMS patients, with a one-year follow-up.

**Methods and analysis.** A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3-months (T1), 6-months (T2), and 12-months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between October 2021 and June 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (e.g., pain intensity, fatigue, and sleep disturbance), and side effects via ecological momentary assessment (EMA) through the Pain Monitor app® during the first three months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with magnetic resonance imaging (MRI) at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitization. Immune-inflammatory biomarkers in serum will also be measured.

**Ethics and dissemination.** This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media, and community engagement activities.

**Trial registration number:** ClinicalTrials.gov (NCT04739995)

### Strengths and limitations of this study

- This is thought to be the first randomised, double-blinded, placebo-controlled phase III trial to assess the efficacy, safety, cost-utility, and neurobiological effects of low-dose naltrexone (LDN) for reducing pain in patients with fibromyalgia syndrome.
- The INNOVA protocol combines mobile-technology-based ecological momentary assessment and assessment with classical legacy measures to obtain more precise information on the dynamics of the assessed primary and secondary outcomes.
- This study will include immune-inflammatory and neuroimaging biomarkers in order to explore the neurobiological underpinnings of LDN.
- This is an adequately powered exploratory trial in which the long-term effects of LDN will be systematically evaluated.

## INTRODUCTION

### **Fibromyalgia: definition, prevalence, and pharmaceutical indications**

Fibromyalgia syndrome (FMS) is a chronic condition of unknown origin that is characterised by generalised musculoskeletal pain, fatigue, stiffness, cognitive problems, sleep disturbances, and malaise.<sup>1,2</sup> This syndrome is highly prevalent in the general population (2.7% worldwide).<sup>3</sup> Around 6% of adult patients who visit their general practitioner, and between 10-20% of those who visit rheumatology services, have FMS.<sup>2</sup> In 2007, the U.S. Food and Drug Administration approved pregabalin as the first drug indicated for the treatment of FMS, and later approved duloxetine and milnacipran for this indication. However, the European regulatory authorities rejected the indication of these three drugs in the treatment of FMS given the small effect sizes in various studies and the associated adverse effects.<sup>4-6</sup>

### **Pathogenesis of FMS**

Although the etiological factors of FMS are not known, the primary hypothesis of the pathogenesis of this syndrome highlights the role of the central nervous system in the amplification of pain perception as well as in the development of comorbid symptoms such as sleep-related problems, fatigue, cognitive difficulties, and emotional distress.<sup>1,7,8</sup> Structural brain alterations have also been found in patients with FMS. For example, lower volumes of grey matter have been observed in areas associated with the processing of stress (e.g., parahippocampal gyrus) and pain (e.g., anterior cingulate cortex, insula, prefrontal cortex, and primary and secondary somatosensory cortices).<sup>7</sup> Functional MRI alterations been associated with self-reported pain intensity. Brain activity exhibited greater connectivity between different pain-processing areas (e.g., insula and secondary somatosensory cortex), the default-model network in persons with FMS, as well as in the association between these areas and the pain levels reported by patients and the right executive attention network.<sup>9</sup>



1  
2  
3 Altered functional connectivity has also been reported among various pain-inhibiting  
4 areas.<sup>10</sup> Some studies have reported reduced levels of neurotransmitters involved in the  
5 regulation of the descending analgesic response (serotonin and noradrenaline) and increased  
6 levels of glutamate (Glu) and substance P in people with FMS.<sup>11</sup> For example, high levels of  
7 Glu have been reported in the posterior insula, posterior cingulate cortex and prefrontal  
8 ventrolateral cortex of patients with FMS when compared to healthy controls<sup>15-18</sup>. Ultimately,  
9 these abnormal levels of brain metabolites seem to be associated with increases in the pain  
10 response, which may facilitate hyperalgesia and allodynia.<sup>11-15</sup>

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 Activation of the microglia could be a contributing factor to the alteration of glutamate  
23 neurotransmission in FMS.<sup>20,21</sup> The microglia is normally found in a state of rest but it is  
24 activated by a wide range of stimuli such as cell death, peripheral inflammation, chronic stress  
25 and infections.<sup>22</sup> Once activated, microglia release pro-inflammatory agents such as cytokines,  
26 excitatory amino acids and nitric oxide.<sup>23</sup> These inflammatory factors across multiple neural  
27 pathways can induce hyperalgesia, fatigue, depression and other symptoms which are known  
28 collectively as “cytokine induced sickness behavior”.<sup>24,25</sup> Microglia activation might trigger a  
29 series of actions that lead to an increase in Glu that ultimately results in synaptic dysfunction.<sup>26</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 A recent study using Positron Emission Tomography<sup>27</sup> of translocator protein revealed a  
42 widespread cortical glial activation in patients with FMS, which gives support to the role of  
43 neuroinflammation in the aetiology of FMS. In addition, there is evidence that chronic stress  
44 facilitates the “priming” and exaggerated activation of the microglia.<sup>28</sup>

45  
46  
47  
48  
49  
50 Although FMS is not considered a classic inflammatory disease, there is extensive  
51 evidence that immune-inflammatory pathways play a significant role in the pathogenesis and  
52 maintenance of the syndrome. Cytokines play a key role in immune-inflammatory response  
53 and in boosting the nociceptive response due to their sensitization actions, both on a peripheral  
54 and central level.<sup>31-32</sup> Thus, there is evidence that FMS involves an imbalance in pro-

1  
2  
3 inflammatory (e.g. IL-1, IL-6, IL-17A, and TNF- $\alpha$ ) and anti-inflammatory (e.g. IL-4 and IL-  
4 10) levels of cytokines that could lead to a low-intensity, chronic state of inflammation.<sup>29,30</sup>  
5  
6 Bäckryd and colleagues<sup>30</sup> identified both neuroinflammation and systemic inflammation by  
7  
8 evaluating levels of a broad panel of cytokines and chemokines in cerebrospinal fluid and  
9  
10 plasma.  
11  
12  
13

### 14 **Low-dose naltrexone (LDN): A promising treatment for FMS**

15  
16 Naltrexone is an opioid antagonist medication used to treat opioid and alcohol  
17  
18 dependency. The drug blocks mu-opioid receptors, the delta-opioid receptors and, to a lesser  
19  
20 extent, the kappa-opioid receptors. There is promising evidence to suggest that naltrexone  
21  
22 administered in low doses (i.e., low-dose naltrexone; <5 mg/day) is effective in the  
23  
24 management of some pathologies which present with altered immune-inflammatory pathways,  
25  
26 such as Crohn's disease, multiple sclerosis, or FMS.<sup>33,34</sup> The immune-regulatory effect of LDN  
27  
28 seems to be driven through the inhibition of the Toll-like receptor 4 (TLR-4) activity expressed  
29  
30 in the membrane of various immune system cells (e.g., microglia and macrophages).<sup>33</sup>  
31  
32 Moreover, due to a “rebound effect”, LDN could exert an analgesic effect that strengthens the  
33  
34 endogenous opioid pain inhibitory system. According to this hypothesis, the low-intensity and  
35  
36 intermittent blockade of the opioid receptors generated by LDN induces a compensatory  
37  
38 mechanism that facilitates an increase in the production of endogenous opioids and greater  
39  
40 sensitivity of the system to their effects.<sup>33,34</sup>  
41  
42  
43  
44  
45  
46  
47

48 To date, the effects of LDN in patients with FMS have only been evaluated through  
49  
50 crossover pilot studies that have yielded preliminary results. In the first study conducted with  
51  
52 LDN in FMS, significant reductions in pain, stress, and fatigue levels were observed.<sup>35</sup> In a  
53  
54 subsequent study, significant improvements in daily pain, satisfaction with life and mood were  
55  
56 also observed.<sup>36</sup> In another crossover investigation, the pre and post changes in the levels of  
57  
58 plasma cytokines were evaluated over eight weeks. Significant reductions in a wide range of  
59  
60

1  
2  
3 immune-inflammatory markers were obtained (e.g., IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, IL-10, IL-17A,  
4 and TNF- $\alpha$ ), together with a reduction in the pain levels and the severity of FMS symptoms.<sup>37</sup>  
5  
6  
7

8 While acknowledging the contribution of past studies into the field, these have included  
9  
10 small sample sizes (n= 8 to 31 participants) and crossover designs. Therefore, a single-site,  
11  
12 prospective, randomised, double-blinded, placebo-controlled study (RCT) with a sufficiently  
13  
14 powered sample is presented here to conduct a methodologically robust investigation into the  
15  
16 role of LDN in FMS. Specifically, the main objective of the INNOVA study is to evaluate the  
17  
18 efficacy, safety, and cost-utility, and neurobiological effects of LDN to reduce pain in FMS.  
19  
20 There is currently no gold standard pharmacological treatment for pain reduction in persons  
21  
22 with FMS. Therefore, in the present study, placebo will be used instead of another drug in the  
23  
24 control group.  
25  
26  
27  
28

## 29 **METHODS AND ANALYSIS**

### 30 **Trial design**

31  
32  
33 The randomised controlled trial (RCT) protocol has been developed following the  
34  
35 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)<sup>38</sup>. In addition,  
36  
37 the RCT was approved by European Union Drug Regulating Authorities Clinical Trials  
38  
39 (EudraCT; 2021-002534-16). For reporting purposes, we will follow the guidelines of the  
40  
41 Consolidated Standards of Reporting Trials (CONSORT)<sup>39</sup> and the Consolidated Health  
42  
43 Economic Evaluation Reporting Standards (CHEERS) statement.<sup>40</sup> INNOVA is a 12-month  
44  
45 double-blind RCT with two arms: LDN vs. Placebo. LDN will be considered an add-on  
46  
47 treatment to the usual care provided in the Spanish National Health System for FMS. For  
48  
49 transparency and analytical reproducibility purposes, the dataset and data coding will be  
50  
51 deposited in the Open Science Framework.  
52  
53  
54  
55  
56

### 57 **Sample size**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

There are no previous RCTs about the efficacy of LDN for FMS, therefore, we estimated the sample size taking into account a previous LDN crossover study<sup>36</sup> that had used self-reported pain as main outcome (the effect size was  $d = .99$ ). Thus, with a sample of 60 participants per arm, we aim to detect between-group differences with a significance level of 5% and a power of 80%. Allowing for a potential attrition rate of 20%, our final sample size is 60 participants per group. For the analysis of biomarkers (involving 50% of the sample), an initial sample size of 30 patients per arm is considered sufficient according to previous studies.<sup>37,41</sup>

### Eligibility criteria

*General selection criteria.* All participants will meet the following inclusion criteria: women between 18-70 years; diagnoses of FMS according to American College of Rheumatology 2016 criteria<sup>42</sup> by a rheumatologist; pain intensity ranked  $\geq 4$  out of 10 on a 10-point numerical rating scale in the past week; fluent in Spanish; provision of written informed consent; stable pharmacological treatment in the last two months; and having a smartphone with android operating system for Ecological Momentary Assessment (EMA). Potential participants will be excluded according to the following exclusion criteria: treatment with naltrexone, opioids, anticoagulants, or central anti-hypertensives in the last 3 months; diagnosis of severe medical/psychiatric disorders (e.g., cancer, haematological diseases, abnormal hepatic/liver function, renal failure, suicide ideation, psychotic disorder); pregnant (or planning to become pregnant during the study period) or breastfeeding; known allergy to naltrexone, naloxone or excipients; currently participating in other RCTs; ongoing litigation related to FMS.

*Additional selection criteria for the biomarkers and neuroimaging sub-study (50% of patients in each study arm).* All participants will meet the following inclusion criteria: right-handed (for the neuroimaging tests); and no comorbid rheumatologic conditions (e.g.,

1  
2  
3 rheumatoid arthritis, lupus). Potential participants will be excluded according to the following  
4  
5 exclusion criteria: fever ( $> 38^{\circ}\text{C}$ ); infection in the last two weeks; vaccination in the last month;  
6  
7 taking cortisone or anti-cytokine therapy; needle phobia or claustrophobia, metal implants or  
8  
9 pacemakers; body mass index  $\geq 36 \text{ kg/m}^2$ ; smoking over 5 cigarettes/day; presence of acute  
10  
11 pain (e.g, headache or back pain) unrelated to FMS on the day of the scan.  
12  
13

### 14 15 **Recruitment strategy, procedure and randomisation**

16  
17 Patients diagnosed with FMS with an appointment at the Rheumatology Service of Parc  
18  
19 Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) will be invited to participate in the  
20  
21 study and will be asked to attend a screening evaluation with a research assistant and a clinician.  
22  
23 Once the informed consent is obtained, the clinician will review the study selection criteria to  
24  
25 confirm eligibility. The week after, a face-to-face assessment (T0) including clinical history  
26  
27 and variables related to the use of services will be conducted with those patients meeting all  
28  
29 the eligibility criteria. Only the participants that are included in the biomarkers sub-study will  
30  
31 require an additional blood extraction and neuroimaging scan, which will be performed in the  
32  
33 following 3-5 days. Participants will be given a sealed envelope with an identifying code which  
34  
35 they will have to take to the pharmacy service. There, they will be given the dose of the  
36  
37 corresponding drug (according to the randomisation) for the first 3 months (90 tablets). As  
38  
39 shown in the patients' flow chart (Figure 1), further in-person evaluations will be performed at  
40  
41 3 months (T1), 6 months (T2), and 12 months (T3). Neurobiological variables will be obtained  
42  
43 at T1 using the same protocol as in the baseline assessment (T0).  
44  
45  
46  
47  
48

49  
50 Participants will be asked to abstain from taking any analgesic or anti-inflammatory  
51  
52 drug in the 72h prior to the blood extractions/scans. All patients, including those who do not  
53  
54 participate in the biomarker sub-study, shall be subjected to a blood test at baseline. Participants  
55  
56 will return to the pharmacy service every 3 months and will be given the assigned amount of  
57  
58 LDN/placebo for the following 3 months (approximately 90 tablets). Unconsumed tablets will  
59  
60

1  
2  
3 be returned for treatment adherence monitoring. The randomisation to conditions will be  
4  
5 conducted by a biostatistician from the Clinical Trials Unit of Fundació Sant Joan de Déu who  
6  
7 has no involvement in the eligibility screening, enrolment, and treatment processes. The  
8  
9 computer-generated randomisation will apply a permuted block design to ensure that the study  
10  
11 arms are balanced taking the biomarkers sub-study eligibility criteria into account. As this is a  
12  
13 double-blind RCT, neither the patient nor the evaluator or the clinician will know to which  
14  
15 treatment arm each patient has been assigned. Only the clinical trial pharmacist who stores and  
16  
17 delivers capsules, but is not involved in patient care, will know the allocation.  
18  
19  
20

21  
22 Figure 1  
23

#### 24 **Data management, central monitoring and audit**

25  
26 The clinical data entry, data management, and central monitoring will be performed  
27  
28 with REDCap®. An independent Clinical Research Organization (CRO) will be responsible  
29  
30 for overseeing the intra-study data sharing and storing process. Any modifications in the study  
31  
32 protocol will be communicated to the CRO.  
33  
34

#### 35 **Treatments**

36  
37  
38 **Low-dose naltrexone (LDN).** The intervention group will take one 4.5 mg naltrexone  
39  
40 tablet (lactose-free) daily for 12 months before going to sleep.  
41  
42

43 **Placebo.** The control group will take the placebo daily for 12 months (a film-coated  
44  
45 tablet identical to the LDN and filled with a lactose-free filler). For the control arm, the same  
46  
47 guidelines will be followed.  
48  
49

50 In order to maintain the external validity of the study and for ethical reasons, the study  
51  
52 participants' active treatments will be unchanged by this clinical trial. In Spain, chronic pain  
53  
54 management is mainly managed by general practitioners in regular consultations. These  
55  
56 generally consist of face-to-face appointments with a duration of 5-10 minutes in which the  
57  
58 clinicians monitor the physical and, ideally, the emotional status of the patient. General  
59  
60

1  
2  
3 practitioners usually provide advice prescribe pharmacotherapy (pain killers, hypnotics,  
4 antidepressants, etc.) or refer patients to pain units in tertiary hospitals when more specialised  
5 pain management procedures are required. The frequency of consultations is based on the type  
6 of disease and its severity. In this study, usual care will be the same as in routine daily practice,  
7 without any modifications. In addition, participants will be allowed to withdraw from this study  
8 for any reason at any time without detriment to the provision or quality of their usual care. If a  
9 severe adverse event occurs, unblinding will be possible and study participation will be  
10 discontinued. If the adverse effects are tolerable, the treatment will be administered until the  
11 end of the study. All these events will be recorded and reported at the end of the study.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 **Study measures**

25  
26 All participants will be assessed with a computer-administered battery of measures  
27 using the REDCap® software (see Table 1).  
28  
29

30  
31 Table 1  
32

### 33 **Measures for sociodemographic characteristics, clinical features, and screening**

34  
35 A *sociodemographic questionnaire* will be used to obtain information about the  
36 following variables: gender, date of birth, marital status, living arrangements, educational level,  
37 income level, and employment status.  
38  
39  
40  
41

42 The *Clinical data* interview will be used to collect information about history and  
43 duration of FMS symptoms, as well as family history of medical/mental illness. Information  
44 regarding comorbidity with other diagnosed physical-psychiatric conditions and the type and  
45 dose of current drugs will be checked from medical records.  
46  
47  
48  
49  
50

51 The *Fibromyalgia Survey Diagnostic Criteria* (FSDC)<sup>43,44</sup> is a 6-item self-report  
52 measure of the core FMS symptoms according to the latest revision of the American College  
53 of Rheumatology (ACR) 2016 criteria.<sup>42</sup> It includes two subscales: the Widespread Pain Index,  
54 which is used to identify the presence of pain in 19 body areas in the last week, and the  
55  
56  
57  
58  
59  
60

1  
2  
3 Symptom Severity Scale, in which the three major FMS symptoms (fatigue, “fibrofog” and  
4 waking up tired) are assessed along with three additional symptoms (pain in the lower stomach,  
5 depression and headache). A total score is obtained by adding the two subscales. This total  
6 score ranges from 0 to 31, where higher values indicate greater FMS severity.  
7  
8  
9

### 10 11 12 **Primary outcome measure**

13  
14  
15 The *Numeric Rating Scale* (NRS)<sup>45</sup> is a unidimensional measure of pain intensity  
16 mainly used for adults. The most frequently used version is an 11-point numeric scale (a  
17 horizontal bar or line) scored from 0 (“no pain”) to 10 (“worst pain imaginable”). Time frames  
18 vary between studies. In the present study, respondents will be asked to report average pain  
19 intensity over the last week.  
20  
21  
22  
23  
24  
25

### 26 27 **Secondary outcome measures**

28  
29 The *Revised Fibromyalgia Impact Questionnaire* (FIQR)<sup>46</sup> includes 21 items that are  
30 answered on a 0 to 10 numerical scale in which higher scores indicate greater functional  
31 impairment. The questionnaire asks about the previous seven days. The items are distributed  
32 into three domains: physical impairment, overall impact, and severity of symptoms (i.e., pain,  
33 energy, stiffness, sleep quality, depression, memory issues, anxiety, pain to the touch, balance  
34 problems and increased sensitivity to noises, lights, smells, or temperatures). A total score is  
35 obtained by summing the three subscale scores. This can range from 0 to 100. Higher scores  
36 indicate greater impairment. The Spanish version of the FIQR and has obtained high internal  
37 consistency estimates ( $\alpha = .91 - .95$ ), adequate test-retest reliability indices ( $r = .82$ ), and good  
38 construct validity.<sup>47</sup>  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 The *Depression Anxiety Stress Scales-21* (DASS-21)<sup>48</sup> is a self-report scale developed  
52 to discriminate between features of depression (anhedonia/low positive affect), anxiety  
53 (physical arousal) and stress (psychological tension/agitation) in clinical and non-clinical  
54 samples. The DASS has been validated in patients with FMS.<sup>49</sup> Responders are required to  
55  
56  
57  
58  
59  
60



1  
2  
3 indicate the presence of a symptom over the previous week. Each item is scored from 0 (“did  
4 not apply to me at all over the last week”) to 3 (“applied to me very much or most of the time  
5 over the past week”). There are seven items on each of the three subscales: depression, anxiety,  
6 and stress. Therefore, total scores in each scale can range from 0 to 21. Higher scores indicate  
7 more severe levels of depression, anxiety and stress. The Spanish version showed adequate  
8 internal consistency for depression ( $\alpha = .84$ ), anxiety ( $\alpha = .70$ ) and stress ( $\alpha = .82$ ).<sup>50</sup>  
9

10  
11  
12 The *Multidimensional Inventory of Subjective Cognitive Impairment* (MISCI)<sup>51</sup> is a  
13 10-item self-report measure of subjective cognitive dysfunction (i.e., “fibrofog”) in FMS.  
14 Each item is scored from 1 (“never”) to 5 (“very often”) and the total score ranges from 10 to  
15 50. Lower scores indicate higher cognitive dysfunction. The MISCI showed excellent internal  
16 reliability, low ceiling/floor effects and good convergent validity with a similar measure. The  
17 Spanish version of the MISCI had sound psychometric properties ( $\alpha = .91$  and ICC = .88).<sup>52</sup>  
18  
19

20  
21  
22 The *World Health Organization Disability Assessment Schedule 2.0* (WHODAS  
23 2.0)<sup>53</sup> is a 12-item self-report measure of the level of difficulty experienced taking into  
24 consideration how they usually do the activity. This includes the use of any devices to assist  
25 them and/or the help of a person. In each item, individuals estimate the magnitude of the  
26 disability during the previous 30 days using a five-point scale scored from 1 (none) to 5  
27 (extreme/cannot do). The total score ranges from 0 to 100. Higher scores reflect greater  
28 disability. The 12-item WHODAS 2.0 has sound psychometric properties in patients with  
29 FMS.<sup>54</sup>  
30

31  
32  
33 The *Generalized Anxiety Disorder 7-item scale* (GAD-7)<sup>55</sup> is a 7-item self-report  
34 measure of pathological worry. Each item is scored from 0 (“not at all”) to 3 (“nearly every  
35 day”). The total score ranges from 0 to 21, where higher scores reflecting greater anxiety  
36 symptoms. The GAD-7 has sound psychometric properties ( $\alpha = .92$  and ICC = .83) in patients  
37 with FMS in previous studies.<sup>56</sup>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Other measures

The *ACTION AE* is a *reporting checklist* used to measure safety and benefit-risk of a clinical trial.<sup>57</sup> The Safety and Benefit-Risk Reporting and Evaluation (SABRRE) Working Group of the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTION; <http://www.action.org>) public-private partnership with the FDA developed an adverse events (AE) reporting checklist that will be used in the present study.

The *EuroQoL* (version EQ-5D-5L)<sup>58</sup> is a health-related quality of life questionnaire that consists of two parts. In the first one, the individual's difficulties concerning mobility, self-care, pain/discomfort and anxiety/depression are evaluated. In the second part, the perceived health is assessed by means of a Visual Analogue Scale ranging from 0 to 100. The EQ-5D-5L scores will be used to calculate the Quality-Adjusted Life Years (QALYs) during the follow-up period by adjusting the duration of time affected by the health outcome by the value of the utility.

The *Client Service Receipt Inventory* (CSRI)<sup>59</sup> is a self-report tool used to collect retrospective data on medication consumption and service receipt. Patients are asked to bring their daily medication prescriptions and information about pain-related drugs (analgesics, anti-inflammatories, opioids, muscle relaxants, antidepressants, etc.) is recorded. This includes the name of the drug, the dosage, total number of prescription days and daily dosage consumed. Concerning service receipt, patients are asked about the total appointments for accident and emergency services, total number of general inpatient hospital admissions, number of diagnostic tests administered and total appointments with healthcare professionals for pain management (family physicians, nurses, social workers, psychologists, psychiatrists, group psychotherapy and other community healthcare professionals). The CSRI will be administered on two occasions: at baseline and at 12-month follow-up, both referring to the

1  
2  
3 previous 12 months. Medical records will be checked to verify the accuracy of the collected  
4  
5 data.  
6  
7

8 The *Patient Global Impression of Change* (PGIC) measures meaningful change in  
9  
10 overall status and the *Pain Specific Impression of Change* (PSIC)<sup>60</sup> measures the perception  
11  
12 of pain improvement. The most frequently used scale is a 7-point numerical scale scored from  
13  
14 1= “much better”) to 7= “much worse”).  
15  
16

### 17 **Ecological momentary assessment (EMA)**

18  
19 Pain intensity and other pain-related variables (e.g., depressive-anxious symptoms and  
20  
21 activity level) can fluctuate during the day and across days depending on personal and  
22  
23 environmental factors. Collecting self-reported data prospectively and closer in time to its  
24  
25 occurrence substantially improves the accuracy, reliability and quality of data. EMA has been  
26  
27 successfully performed in patients with a variety of physical and mental problems.<sup>61,62</sup> There  
28  
29 is growing evidence indicating that well-designed smartphone apps can be easy to use and well-  
30  
31 tolerated even in relatively old pain populations, with compliance rates as high as 85%.<sup>61</sup> In  
32  
33 this RCT, we will use the Pain Monitor® (Monitor de Dolor, by its Spanish name) app<sup>63</sup> to  
34  
35 assess a wide range of variables (see items in Table 2) twice a day (once in the morning and  
36  
37 once in the evening, at convenient times along the week) during 120 days. The app and the data  
38  
39 will be stored on different servers with different domain names and connected locally only (the  
40  
41 server containing the data does not have Internet access). According to a recent meta-analysis,<sup>64</sup>  
42  
43 EMA-completion rates are higher among elderly patients compared to younger patients.  
44  
45 Considering that the majority of FMS patients in our study are not expected to be young and  
46  
47 that the EMA item battery does not require a long response time (< 1 min.), it is expected not  
48  
49 to place an excessive burden on participants.  
50  
51  
52  
53  
54  
55

56 Table 2

### 57 **Immune-inflammatory markers**

1  
2  
3 After obtaining the blood sample, it will be allowed to coagulate for a minimum of 30  
4 minutes at room temperature. It will then be centrifuged for 10 minutes at 1000g. The resulting  
5 serum will be stored at -80° C during the same morning of extraction until it is ready to be  
6 analysed. All samples (at T0 and T1) will be analysed in a single analytical batch to reduce  
7 inter-assay variability (approx. 15%). The serum levels of IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, sIL-6r,  
8 sgp130, CXCL-8, IL-10, IL-17, TNF- $\alpha$ , and high-sensitivity C-reactive protein (hs-CRP) will  
9 be evaluated.<sup>29</sup> For the quantification of the cytokines, the Milliplex® reagents from the  
10 company MerckMillipore® will be used and analysed using a Luminex® platform. The high  
11 sensitivity multiplex kit will be used: Human High Sensitivity T Cell, catalogue number:  
12 HSTCMAG28SPMX11, adapted to the aforementioned cytokines. The hs-PCR will be  
13 quantified using turbidimetry in an Olympus AU5400 auto-analyser. These biomarkers will  
14 only be evaluated at baseline (T0) and 3-months (T1) for the following reasons: (a) there is  
15 evidence of significant inflammatory changes at 8 weeks with LDN;<sup>37</sup> (b) this results in lower  
16 risk of dropout (vs. evaluating them at 6 or 12 months); (c) conducting at least two measures  
17 allows to use the change between baseline and 3-months as a mediator of long-term clinical  
18 changes; and (d) budget constraints.

### 40 Neuroimaging

41  
42 The scans (protocol duration: approximately 30 minutes) will be performed in a  
43 Phillips Ingenia 3T MRI scanner with a 32-channel head coil at Hospital Sant Joan de Déu  
44 (Esplugues de Llobregat, Spain). To examine cingulate, insular, amygdalar, occipital, angular,  
45 parahippocampal, and prefrontal gray matter volume, we will use voxel-based morphometry  
46 (VBM). We will also use surface-based morphometry (with FreeSurfer calculation of cortical  
47 thickness, surface area, and local gyrification index) for examining cortical abnormalities.  
48 Additionally, glutamate, glutamine, myo-inositol, N-acetylaspartate, choline, and creatine  
49 (and creatinine ratios) levels will be analysed using magnetic resonance spectroscopy.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Specifically, we will conduct the following processing for the regions of interest according to  
4 the corresponding hypotheses. For VBM, we will apply a bias field correction, tissue  
5 segmentation with SPM12, normalization with DARTEL, modulation, and smoothing. We  
6 will use both unmodulated and modulated grey matter images to convey complementary  
7 volumetric information. We will use FreeSurfer ENIGMA pipelines to perform the VBM. In  
8 addition, we will quantify metabolites concentrations using LCModel (v6.3-1J). We will only  
9 include high-quality spectra, defined as signal-to-noise ratio  $> 15$ , Cramer-Rao lower bounds  
10  $< 15\%$ , and full width at half maximum of metabolites  $< .07$ . The spectroscopy analysis will  
11 account for the effects of cerebrospinal fluid and grey matter within the voxel, and inter-  
12 individual differences in cortical grey matter.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

### 25 26 **Statistical analysis**

27  
28 The main analysis will compare the effect of LDN vs. placebo on the primary outcome  
29 (pain intensity at T1). Data analyses will be performed following an intention-to-treat (ITT)  
30 plan. Then, we will compute analysis of the primary outcome (at T2 and T3) and analysis of  
31 the secondary outcomes at T1, T2 and T3. Linear mixed models will be created using the  
32 restricted maximum likelihood method for the estimation of parameters. The effect sizes will  
33 be calculated according to Cohen's *d*. An interim analysis is planned at T1 once 50% of the  
34 total sample has been evaluated. A 5% significance level will be used in all two-tailed tests,  
35 applying the Benjamini-Hochberg correction for multiple comparisons. Additionally, to make  
36 the findings from our study clinically meaningful, the number needed to treat will be reported.  
37 For this analysis, we will dichotomise participants into responders or non-responders using two  
38 different cut-off criteria in compliance with the IMMPACT recommendations:<sup>45</sup> At least 50%  
39 pain relief over baseline (substantial benefit) or 30% or more pain relief (moderate benefit).  
40 For these analyses, we will use SPSS v26 (IBM Corp, Armonk, NY, USA).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Regarding EMA, a recent recommended approach is "network analysis". There has been burgeoning interest in conceptualizing chronic pain as a network of interacting symptoms and psychobiological processes.<sup>65</sup> Network analysis will offer us a good chance to quantify and visualize relationships between pain intensity and pain-related variables (e.g., depression, anxiety, fatigue, sleep disturbance). We will estimate temporal networks by means of vector autoregression techniques;<sup>66</sup> These "temporal networks", would indicate potential causality with one or more variables preceding one or more variables in time. Network analysis will be performed with the free statistical software JASP.<sup>67</sup>

In economic evaluation, it is important to calculate the relationship between the costs of each treatment and its consequences in the form of QALYs, an index measure designed to assess both quantity of life (years) and health-related quality of life. A year lived with the maximum quality of life would be transformed into 1 QALY; a year lived with half the maximum quality of life would be transformed into 1/2 QALY. This relative value is called the incremental cost-utility ratio (ICUR) and it expresses the relationship between the costs and the effects of one option compared to another. The QALYs obtained in the 12 months after the treatment onset will be calculated by the area under the curve. The direct costs will be calculated by adding together the costs derived from the medication and the use of the health services. The cost of medications will be calculated by multiplying the price per milligram by the total daily dose consumed (in milligrams) and the number of days that the treatment is received. The cost arising from the use of the health services (primary care, specialist and accident and emergency consultations, and hospital admissions) will be obtained from the clinical electronic records (<http://www.oblikue.com/en/esalud.html>). The indirect costs will be calculated based on the days off work, which will be multiplied by the official minimum wage during the study period. The effect of the treatments will be estimated using ordinary least squares multivariate regression, adjusting for the baseline differences between groups. In order

1  
2  
3 to manage uncertainty in the sampling distribution of the ICUR, non-parametric bootstrapping  
4 will be applied, with 1000 replications in each comparison. Cost-utility analyses will be  
5 conducted with STATA v16.0 (StataCorp, College Station, TX, USA).  
6  
7  
8  
9

### 10 **Patient and public involvement**

11  
12 Patients and the public will not be involved in the design, conduct, reporting, or  
13 dissemination of our research.  
14

### 17 **ETHICS AND DISSEMINATION**

18  
19  
20 All procedures performed in this study will be in accordance with the 1964 Helsinki  
21 declaration and its last amendments (7<sup>th</sup> revision, adopted by the 64<sup>th</sup> World Medical  
22 Association General Assembly, Fortaleza, Brazil). Signed informed consent will be obtained  
23 from all patients once they have been informed of the study procedures, potential risks, and  
24 their right to withdraw at any time from the RCT. The FSJD Ethics Committee Board evaluated  
25 and approved the study protocol in June 2021 (PIC-178-19). Only the principal investigators  
26 (ARS and JVL) will have full access to the final trial dataset. Modifications in the study  
27 protocol will be reported to the FSJD Ethics Committee Board as well as the independent CRO.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38  
39 Once the RCT is completed, we will publish our results in international peer-reviewed  
40 biomedical journals and present them at national and international conferences. Authorship  
41 will be assigned in accordance with the International Committee of Medical Journal Editors  
42 guidance. In addition, we will send participating patients a short report of our findings. A copy  
43 of the report will also be sent to Institute of Health Carlos III (main funding body). The  
44 principal investigators will organize an end-of-study seminar. The main objective of this  
45 activity will be to share the study findings with stakeholders to discuss how to maximize uptake  
46 of the findings in patient treatment and clinical practice, and to determine future research  
47 directions.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

### 59 **DISCUSSION**

1  
2  
3 As far as we know, no RCT has been published about the efficacy, safety, cost-utility,  
4 and neurobiological underpinnings of LDN in patients with FMS. This manuscript presents the  
5 design and rationale of a randomised, double-blinded, placebo-controlled phase III study,  
6 which is a powerful design to assess the efficacy of LDN. We have decided to administer 4.5  
7 mg/day of LDN in this RCT because this dose seems to provide an optimal balance between  
8 significant analgesic efficacy and minimal side effects (nausea, sleep disturbance, nightmares,  
9 etc.) according to a recent study.<sup>68</sup>

10  
11  
12  
13  
14  
15  
16  
17  
18  
19 Our findings using this design in conjunction with those that will be obtained in another  
20 ongoing RCT that is being carried out in Denmark (The FINAL study)<sup>69</sup> may facilitate the  
21 approval of the first drug indicated for the treatment of FMS in Europe. The FINAL study is  
22 an ongoing single-centre, randomised, double-blinded, placebo-controlled trial that is being  
23 carried out in Odense (Denmark). A total of 100 women between 18–64 years-old with FMS  
24 will take either LDN or placebo for three months. Besides self-report measures, Danish  
25 researchers will also examine the levels of pro- and anti-inflammatory cytokines. If our  
26 respective findings strongly differ in efficacy or safety, we might analyse which factors can  
27 account for the divergence and plan a multi-country confirmatory trial with an agreed design  
28 and methodology. As pointed out by Kim and Fishman<sup>70</sup>, a common problem with a generic,  
29 compounded medication is the lack of commercial support for research. To begin studies such  
30 as INNOVA or FINAL, it is crucial to have the synergistic support from public funding bodies,  
31 private entities, and commercial companies. This has been the case in the present study, with  
32 different public and private organizations providing economic and logistic support.

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52 The inclusion of brain and blood immune-inflammatory biomarkers will allow us to  
53 determine whether LDN modulates neuro-inflammatory processes involving inflammatory  
54 cells such as glial cells. These markers will also allow us to explore the “hormetic” effects of  
55 the drug, that is, if a low dose of an antagonist (naltrexone) may paradoxically act as an agonist  
56  
57  
58  
59  
60



1  
2  
3 of the endogenous opiate system. As explained above, it is posited that LDN mainly acts as an  
4 immunomodulatory drug via blockade of TLR-4, which provides a therapeutic pathway to  
5 reduce activation of the inflammatory cascade and the nociceptive system.<sup>71</sup>  
6  
7  
8  
9

10 Obtaining empirical evidence for cost-utility of treatments or interventions is required  
11 by the Ministry of Health in Spain for reimbursement. In Spain, a threshold of €22,000–25,000  
12 per QALY gained is found to be consistent with decisions of adopting new technologies by the  
13 National Health Service.<sup>72</sup> To our knowledge, there is an absence of economic evaluations for  
14 LDN; therefore, an important feature of the present study is the cost-utility assessment of the  
15 drug.  
16  
17  
18  
19  
20  
21  
22  
23

24 FMS remains a chronic, debilitating, and difficult to manage condition for many  
25 individuals around the world. After three decades of intensive research, the clinical benefits of  
26 pharmacological treatments remain unclear and limited. This study will evaluate the analgesic  
27 efficacy, safety, and cost-utility of LDN using a rigorous and powered design. If efficacious  
28 and cost-effective, LDN might be the first drug approved for FMS in Europe.  
29  
30  
31  
32  
33  
34  
35

### 36 **Trial status**

37  
38 This study is currently in the recruitment phase. The first patient will be enrolled in  
39 October 2021, and the study is expected to end in June 2024.  
40  
41  
42

### 43 **Confidentially**

44  
45 Personal data will be stored in accordance with the Spanish regulation guidelines for  
46 clinical research. Participants will be allocated a unique identification (ID) number at entry.  
47 The master list linking participant personal information and ID number will be maintained in  
48 a password-protected hard drive at the PSSJD. Data will be stored for 10 years after study  
49 completion.  
50  
51  
52  
53  
54  
55

### 56 **Contributors**

JVL, ARS, and AFS conceived the study and revised the manuscript. JVL drafted the manuscript. ACC, JPSM, HHN, XB, CSR, AGP, JM, JM, FDA, MM, JWY, AFS and ARS provided feedback on the manuscript, and all authors reviewed and approved the final version of the manuscript.

### **Funding**

This study has been funded by the Institute of Health Carlos III (ISCIII; ICI20/00080; CPII19/00003) and has been co-financed with European Union ERDF funds. JPS-M has a PFIS predoctoral contract from the ISCIII (FI20/00034). AC-C has a FI predoctoral contract from AGAUR (FI\_B/00216). AF-S and JVL acknowledge the funding from the Serra Húnter program (UAB-LE-8015 and UAB-LE-120014, respectively). The ISCIII did not have any role in the analysis and interpretation of data, in the writing of the manuscript, or in the decision to submit the paper for publication.

### **Competing interests**

None declared.

### **Patient consent for publication**

Not required.

### **Provenance and peer review**

Not commissioned; externally peer reviewed.

**REFERENCES**

1. Häuser W, Ablin J, Fitzcharles MA, *et al.* Fibromyalgia. *Nat Rev Dis Primers* 2015;1:15022.
2. Fietta P, Fietta P, Manganeli P. Fibromyalgia and psychiatric disorders. *Acta Biomed* 2007;78:88-95.
3. Queiroz LP. Worldwide epidemiology of fibromyalgia. *Curr Pain Headache Rep* 2013;17:356.
4. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. *Curr Opin Investig Drugs* 2010;11:16-8.
5. Nüesch E, Häuser W, Bernardy K, *et al.* Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: Network meta-analysis. *Ann Rheum Dis* 2013;72:955-62.
6. Thieme K, Mathys M, Turk DC, *et al.* Evidenced-based guidelines on the treatment of fibromyalgia patients: Are they consistent and if not, why not? Have effective psychological treatments been overlooked? *J Pain* 2017;18:747-56.
7. Cagnie B, Coppieters I, Denecker S, *et al.* Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. *Semin Arthritis Rheum* 2014;44:68-75.
8. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* 2011;152:S2-15.
9. Napadow V, LaCount L, Park K, *et al.* Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. *Arthritis Rheum* 2010;62:2545-55
10. Jensen KB, Berna C, Loggia ML, *et al.* The use of functional neuroimaging to evaluate psychological and other non-pharmacological treatments for clinical pain. *Neurosci Lett* 2012;520:156-64.

11. Zunhammer M, Schweizer LM, Witte V, *et al.* Combined glutamate and glutamine levels in pain-processing brain regions are associated with individual pain sensitivity. *Pain* 2016;157:2248-56.
12. Pyke TL, Osmotherly PG, Baines S. Measuring glutamate levels in the brains of fibromyalgia patients and a potential role for glutamate in the pathophysiology of fibromyalgia symptoms. *Clin J Pain* 2017;33:944-54.
13. Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging in fibromyalgia taught us about the mechanisms and management of centralized pain? *Arthritis Res Ther*, 2014;16:425.
14. Fayed N, Andres E, Rojas G, *et al.* Brain dysfunction in fibromyalgia and somatization disorder using proton magnetic resonance spectroscopy: a controlled study. *Acta Psychiatr Scand* 2012;126:115-25.
15. Fayed N, Garcia-Campayo J, Magallón R, *et al.* Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. *Arthritis Res Ther* 2010;12:R134.
16. Harris RE, Sundgren PC, Craig AD, *et al.* Elevated insular glutamate in fibromyalgia is associated with experimental pain. *Arthritis Rheum* 2009;60:3146-52.
17. Feraco P, Bacci A, Pedrabissi F, *et al.* Metabolic abnormalities in pain-processing regions of patients with fibromyalgia: a 3T MR spectroscopy study. *Am J Neurorad* 2011;32:1585-90
18. Harris RE, Napadow V, Huggins JP, *et al.* Pregabalin rectifies aberrant brain chemistry, connectivity, and functional response in chronic pain patients. *Anesthesiology* 2013;119:1453-64.
19. Murga I, Guillen V, Lafuente JV. Cerebral magnetic resonance changes associated with fibromyalgia syndrome. *Med Clin* 2017;148(11):511-6

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
20. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med* 2004;140:441-51.
  21. Ji RR, Berta T, Nedergaard M, *et al.* Glia and pain: is chronic pain a gliopathy? *Pain* 2013;154:S10-S28.
  22. Lynch MA. The multifaceted profile of activated microglia. *Mol Neurobiol* 2009;40:139-56.
  23. Watkins LR, Hutchinson MR, Ledebner A, *et al.* Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. *Brain Behav Immun* 2007;21:131-46
  24. Kettenmann H, Hanisch UK, Noda M, *et al.* Physiology of microglia. *Physiol Rev* 2011;91:461-553.
  25. Dantzer R. Cytokine, sickness behavior, and depression. *Immunol Allergy Clin North Am* 2009;29:247-64.
  26. Haroon E, Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. *Neuropsychopharmacol* 2017;42:193-215.
  27. Albrecht DS, Forsberg A, Sandström A, *et al.* Brain glial activation in fibromyalgia - A multi-site positron emission tomography investigation. *Brain Behav Immun* 2019;75:72-83.
  28. Niraula A, Sheridan JF, Godbout JP. Microglia priming with aging and stress. *Neuropsychopharmacol.* 2017;42:318.
  29. Andrés-Rodríguez L, Borràs X, Feliu-Soler A, *et al.* Peripheral immune aberrations in fibromyalgia: A systematic review, meta-analysis and meta-regression. *Brain Behav Immun* 2020;87:881-9.
  30. Bäckryd E, Tanum L, Lind AL, *et al.* Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. *J Pain Res* 2017;10:515.

- 1  
2  
3 31. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation  
4 leading to neuropathic pain. *Curr Opin Pharmacol* 2012;12:55 -61.  
5  
6
- 7 32. Miller AH, Haroon E, Raison CL, *et al.* Cytokine targets in the brain: impact on  
8 neurotransmitters and neurocircuits. *Depress Anxiety* 2013;30:297-306.  
9
- 10 33. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel  
11 anti-inflammatory treatment for chronic pain. *Clin Rheumatol* 2014;33:451-9.  
12
- 13 34. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in  
14 the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia,  
15 Crohn's disease, and other chronic pain disorders. *Pharmacotherapy* 2018;38(3):382-9.  
16
- 17 35. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: A  
18 pilot study. *Pain Med* 2009;10(4):663-72.  
19
- 20 36. Younger J, Noor N, McCue R, *et al.* Low-dose naltrexone for the treatment of  
21 fibromyalgia: findings of a small, randomized, double-blind, placebocontrolled,  
22 counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum.* 2013;65:529-  
23 38.  
24
- 25 37. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-  
26 dose naltrexone for fibromyalgia. *Biomedicines.* 2017;5:16.  
27
- 28 38. Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard  
29 protocol items for clinical trials. *Ann Intern Med* 2013;158:200-7.  
30
- 31 39. Schulz KF, Altman DG, Moher D, *et al.* CONSORT 2010 Statement: updated  
32 guidelines for reporting parallel group randomized trials. *BMJ* 2010;340:c332.  
33
- 34 40. Husereau D, Drummond M, Petrou S, *et al.* Consolidated Health Economic Evaluation  
35 Reporting Standards (CHEERS) statement. *BMC Med* 2013;11:80.  
36
- 37 41. Fayed N, Oliván-Blázquez B, Herrera-Mercadal P, *et al.* Changes in metabolites after  
38 treatment with memantine in fibromyalgia. A double blind randomized controlled trial with  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 magnetic resonance spectroscopy with a 6 month follow up. *CNS Neurosci Ther*  
4 2014;20:999-1007.  
5  
6  
7  
8 42. Gálvez-Sánchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia:  
9 Critical Review and Future Perspectives. *J Clin Med* 2020;9(4):1219.  
10  
11  
12 43. Häuser W, Jung E, Erbslöh-Möller B, *et al.* Validation of the fibromyalgia survey  
13 questionnaire within a cross-sectional survey. *PLoS One* 2012;7:e37504.  
14  
15  
16 44. Carrillo-de-la-Peña MT, Triñanes Y, González-Villar A, *et al.* Convergence between  
17 the 1990 and 2010 ACR diagnostic criteria and validation of the Spanish version of the  
18 Fibromyalgia Survey Questionnaire (FSQ). *Rheumatol Int* 2015;35:141–151.  
19  
20  
21  
22 45. Dworkin RH, Turk DC, Wyrwich KW, *et al.* Interpreting the clinical importance of  
23 treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*  
24 2008;9(2):105-21.  
25  
26  
27  
28 46. Bennett RM, Friend R, Jones KD, *et al.* The Revised Fibromyalgia Impact  
29 Questionnaire (FIQR): Validation and psychometric properties. *Arthritis Res Ther*  
30 2009;11:R120.  
31  
32  
33  
34 47. Luciano JV, Aguado J, Serrano-Blanco A, *et al.* Dimensionality, reliability, and validity  
35 of the revised fibromyalgia impact questionnaire in two spanish samples. *Arthritis Care Res*  
36 2013;65:1682–9.  
37  
38  
39  
40 48. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of  
41 the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety  
42 Inventories. *Behav Res Ther* 1995;33:335-43.  
43  
44  
45  
46 49. Alok R., Das SK., Agarwal GG, *et al.* Relationship of severity of depression, anxiety  
47 and stress with severity of fibromyalgia. *Clin Exp Rheumatol* 2011;29(6 Suppl 69):S70-2.  
48  
49  
50  
51 50. Bados A, Solanas A, Andrés R. Psychometric properties of the Spanish version of  
52 Depression, Anxiety and Stress Scales (DASS). *Psicothema* 2005;17:679-83.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
51. Kratz AL, Schilling SG, Goesling J, *et al.* Development and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia. *J Pain* 2015;16:527–36.
52. Feliu-Soler A, Pérez-Aranda A, Andrés-Rodríguez L, *et al.* Digging into the construct of fibrofog: Psychometric properties of the Spanish version of the Multidimensional Inventory of Subjective Cognitive Impairment in patients with fibromyalgia. *J Appl Biobehav Res* 2018:e12134.
53. Vázquez-Barquero JL, Vázquez Bourgón E, Herrera Castanedo S, *et al.* Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): Initial phase of development and pilot study. Cantabria disability work group. *Actas Esp Psiquiatr* 2000;28:77-87.
54. Smedema SM, Yaghmaian RA, Ruiz D, *et al.* Psychometric validation of the world health organization disability assessment schedule 2.0-12-item version in persons with fibromyalgia syndrome. *J Rehabil* 2016;82(3):28-35
55. Spitzer RL, Kroenke K, Williams JB, *et al.* A brief measure for assessing generalized anxiety disorder: The GAD-7. *Arch Intern Med* 2006;166(10):1092-7
56. Robinson RL, Kroenke K, Williams, DA, *et al.* Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the REFLECTIONS study. *Pain Med.* 2013;14(9):1400-15.
57. Smith SM, Wang AT, Katz NP, *et al.* Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTION systematic review and recommendations. *Pain* 2013;154(7):997-1008.
58. Herdman M, Gudex C, Lloyd A, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
59. Vázquez-Barquero JL, Gaité L, Cuesta MJ, *et al.* Spanish version of the CSRI: a mental health cost evaluation interview. *Arch Neurobiol (Madr)* 1997;60:171-84.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
60. Scott W, McCracken LM. Patients' impression of change following treatment for chronic pain: global, specific, a single dimension, or many? *J Pain* 2015;16:518–26.
61. May M, Junghaenel DU, Ono M, *et al.* Ecological momentary assessment methodology in chronic pain research: A systematic review. *J Pain* 2018;19:699-716.
62. Colombo D., Fernández-Álvarez J, Patané, A, *et al.* Current state and future directions of technology-based ecological momentary assessment and intervention for major depressive disorder: a systematic review. *J Clin Med* 2019;8(4):465.
63. Suso-Ribera C, Castilla D, Zaragoza I, *et al.* Validity, reliability, feasibility, and usefulness of Pain Monitor: A multidimensional smartphone app for daily monitoring of adults with heterogeneous chronic pain. *Clin J Pain* 2018;34:900-8.
64. Ono M, Schneider S, Junghaenel DU, *et al.* What affects the completion of ecological momentary assessments in chronic pain research? An individual patient data meta-analysis. *J Med Internet Res* 2019;21(2):e11398
65. Penedo JMG, Rubel JA, Blättler L, *et al.* The complex interplay of pain, depression, and anxiety symptoms in patients with chronic pain: A network approach. *Clin J Pain* 2020;36:249-59
66. Bringmann LF, Vissers N, Wichers M, *et al.* A network approach to psychopathology: new insights into clinical longitudinal data. *PloS One* 2013;8(4)
67. Love J, Selker R, Marsman M, *et al.* JASP: Graphical statistical software for common statistical designs. *J Stat Softw* 2019;88(2):1-17.
68. Bruun-Plesner KD, Blichfeldt-Eckhardt MR, Vaegter HB, *et al.* Low-dose naltrexone for the treatment of fibromyalgia: Investigation of dose–response relationships. *Pain Med* 2020;21(10):2253-61.

- 1  
2  
3 69. Bruun-Plesner KD, Amris K, Vaegter, HB, *et al.* Low dose naltrexone for the treatment  
4 of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial, 08 April  
5 2021, PREPRINT (Version 1) available at *Research Square*.  
6  
7  
8  
9  
10 70. Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic  
11 review. *Curr Pain Headache Rep* 2020;24(10):1-8  
12  
13  
14 71. Hatfield E, Phillips K, Swidan S, *et al.* Use of low-dose naltrexone in the management  
15 of chronic pain conditions: A systematic review. *J Am Dent Assoc* 2020;151(12):891-902.  
16  
17  
18 72. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a  
19 cost-effectiveness threshold for the Spanish NHS. *Health Econ* 2018;27(4):746-61.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Time points for data collection.

Measures	T0 (baseline)	T1 (3-m)	T2 (6-m)	T3 (12-m)
<i>Sociodemographic, clinical, and screening measures</i>				
Sociodemographic data	X			
Clinical data (years of evolution, comorbidities, etc.)	X			
FSDC screening and secondary outcome measure (fibromyalginess)	X	X	X	X
<i>Primary outcome measure</i>				
NRS (pain intensity)	X	X	X	X
<i>Secondary outcome measures</i>				
FIQR (functional impairment)	X	X	X	X
DASS-21 (anxiety, depression, and stress)	X	X	X	X
MISCI (subjective cognitive impairment)	X	X	X	X
WHODAS 2.0 (disability)	X	X	X	X
GAD-7 (general anxiety / worry)	X	X	X	X
<i>Other measures</i>				
EQ-5D-5L (quality of life)	X			X
CSRI (medication consumption and service receipt)	X			X
PGIC and PSIC (impression of change)		X	X	X
ACTTION checklist (adverse events throughout the trial)	X	X	X	X
Pain Monitor® app (EMA)	X	X		
<b>Physiological variables</b>				
Immune-inflammatory markers	X	X		
Neuroimaging	X	X		

ACTTION checklist: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; CSRI: Client Service Receipt Inventory; DASS-21: Depression Anxiety Stress Scales-21; EQ-5D-5L: EuroQoL; EMA: Ecological Momentary Assessment; FIQR: Fibromyalgia Impact Questionnaire Revised; FSDC: Fibromyalgia Survey Diagnostic Criteria; GAD-7: Generalized Anxiety Disorder 7-item scale; NRS: Numerical Pain Rating Scale; PGIC and PSIC= Patient Global Impression of Change and Pain Specific Impression of Change; WHODAS 2.0: 12-item interviewer administered version of the World Health Organization Disability Assessment Schedule 2.0

**Table 2.** List of items administered via Pain Monitor® app.


Items	Morning	Evening
Pain intensity	X	X
Fatigue	X	X
Perceived control over pain	X	X
Depression	X	X
Anxiety	X	X
Stress	X	X
Sleep disturbance	X	
Activity level		X
Interference with leisure activities		X
Interference with work-related activities		X
Adverse effects		X
Rescue medications		X

The Pain Monitor app automatically informs patients when to respond (by default, at 11 AM and 7 PM) using a push notification system, but patients can respond with a margin of 2 hours from given times. Collected data are stored on a secure server at the Jaume I University, Spain.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Flowchart of the INNOVA study based on the CONSORT guidelines.

For peer review only



190x275mm (96 x 96 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item N°	Description	Pages
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration	2b	All items from the World Health Organization Trial Registration Data Set	n.a
	3	Date and version identifier	n.a
Protocol version	3	Date and version identifier	n.a
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,23
	5b	Name and contact information for the trial sponsor	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-8
	6b	Explanation for choice of comparators	8
Objectives	7	Specific objectives or hypotheses	8

1			
2		Description of trial design including type of trial (eg, parallel	
3		group, crossover, factorial, single group), allocation ratio, and	
4	Trial design	8 framework (eg, superiority, equivalence, noninferiority,	8
5		exploratory)	
6			
7			
8		<b>Methods: Participants, interventions, and outcomes</b>	
9			
10		Description of study settings (eg, community clinic, academic	
11	Study setting	9 hospital) and list of countries where data will be collected.	10
12		Reference to where list of study sites can be obtained	
13			
14		Inclusion and exclusion criteria for participants. If applicable,	
15	Eligibility criteria	10 eligibility criteria for study centres and individuals who will	9
16		perform the interventions (eg, surgeons, psychotherapists)	
17			
18			
19		Interventions for each group with sufficient detail to allow	
20		11a replication, including how and when they will be administered	11
21			
22		Criteria for discontinuing or modifying allocated interventions for	
23		11b a given trial participant (eg, drug dose change in response to	12
24		harms, participant request, or improving/worsening disease)	
25	Interventions		
26		Strategies to improve adherence to intervention protocols, and	
27		11c any procedures for monitoring adherence (eg, drug tablet return,	10
28		laboratory tests)	
29			
30		Relevant concomitant care and interventions that are permitted	
31		11d or prohibited during the trial	11
32			
33			
34		Primary, secondary, and other outcomes, including the specific	
35		measurement variable (eg, systolic blood pressure), analysis	
36		metric (eg, change from baseline, final value, time to event),	12-18
37	Outcomes	12 method of aggregation (eg, median, proportion), and time point	Table 1
38		for each outcome. Explanation of the clinical relevance of	Table 2
39		chosen efficacy and harm outcomes is strongly recommended	
40			
41			
42		Time schedule of enrolment, interventions (including any run-ins	
43	Participant	13 and washouts), assessments, and visits for participants. A	Fig. 1
44	timeline	schematic diagram is highly recommended (see Figure)	
45			
46		Estimated number of participants needed to achieve study	
47		objectives and how it was determined, including clinical and	
48	Sample size	14 statistical assumptions supporting any sample size calculations	9
49			
50			
51		Strategies for achieving adequate participant enrolment to reach	
52	Recruitment	15 target sample size	10
53			

**Methods: Assignment of interventions (for controlled trials)**

Allocation:



1				
2			Method of generating the allocation sequence (eg, computer-	
3			generated random numbers), and list of any factors for	
4	Sequence		stratification. To reduce predictability of a random sequence,	
5	generation	16a	details of any planned restriction (eg, blocking) should be	10
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocation		Mechanism of implementing the allocation sequence (eg, central	
11	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
12	mechanism	16b	describing any steps to conceal the sequence until interventions	10
13			are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence, who will enrol	10
16			participants, and who will assign participants to interventions	
17				
18				
19			Who will be blinded after assignment to interventions (eg, trial	
20		17a	participants, care providers, outcome assessors, data analysts),	10-11
21			and how	
22	Blinding (masking)			
23			If blinded, circumstances under which unblinding is permissible,	
24		17b	and procedure for revealing a participant's allocated intervention	11
25			during the trial	
26				
27				
28	<b>Methods: Data collection, management, and analysis</b>			
29				
30			Plans for assessment and collection of outcome, baseline, and	
31			other trial data, including any related processes to promote data	
32			quality (eg, duplicate measurements, training of assessors) and	
33		18a	a description of study instruments (eg, questionnaires,	12-18
34			laboratory tests) along with their reliability and validity, if known.	
35	Data collection		Reference to where data collection forms can be found, if not in	
36	methods		the protocol	
37				
38				
39			Plans to promote participant retention and complete follow-up,	
40		18b	including list of any outcome data to be collected for participants	10
41			who discontinue or deviate from intervention protocols	
42				
43				
44			Plans for data entry, coding, security, and storage, including any	
45			related processes to promote data quality (eg, double data entry;	
46	Data management	19	range checks for data values). Reference to where details of	11
47			data management procedures can be found, if not in the	
48			protocol	
49				
50				
51			Statistical methods for analysing primary and secondary	
52		20a	outcomes. Reference to where other details of the statistical	18-19
53	Statistical		analysis plan can be found, if not in the protocol	
54	methods			
55				
56		20b	Methods for any additional analyses (eg, subgroup and adjusted	19-20
57			analyses)	
58				
59				
60				

		Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	18
		<b>Methods: Monitoring</b>	
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	18
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	11
		<b>Ethics and dissemination</b>	
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	21
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	21
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n.a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	24
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	21

1				
2	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for	n.a
3	trial care		compensation to those who suffer harm from trial participation	
4				
5			Plans for investigators and sponsor to communicate trial results	
6			to participants, healthcare professionals, the public, and other	
7		31a	relevant groups (eg, via publication, reporting in results	21
8			databases, or other data sharing arrangements), including any	
9			publication restrictions	
10	Dissemination			
11	policy			
12		31b	Authorship eligibility guidelines and any intended use of	24
13			professional writers	
14				
15		31c	Plans, if any, for granting public access to the full protocol,	8
16			participant-level dataset, and statistical code	
17				
18				
19	<b>Appendices</b>			
20	Informed consent	32	Model consent form and other related documentation given to	Attached
21	materials		participants and authorised surrogates	
22				
23			Plans for collection, laboratory evaluation, and storage of	
24	Biological	33	biological specimens for genetic or molecular analysis in the	17
25	specimens		current trial and for future use in ancillary studies, if applicable	
26				
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055351.R1
Article Type:	Protocol
Date Submitted by the Author:	27-Oct-2021
Complete List of Authors:	Colomer-Carbonell, Ariadna; Institut de Recerca Sant Joan de Déu, Teaching, Research & Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology Sanabria-Mazo, Juan; Institut de Recerca Sant Joan de Déu, Teaching, Research & Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology Hernández-Negrín, Halbert; Universidad de Ciencias Médicas de Villa Clara Borràs, Xavier; Autonomous University of Barcelona, Susó-Ribera, Carlos; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology García-Palacios, Azucena; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology Muchart, Jordi; Hospital Sant Joan de Déu, Diagnostic Imaging Department Munuera, Josep; Hospital Sant Joan de Déu, Diagnostic Imaging Department D'Amico, Francesco; London School of Economics and Political Science, Personal Social Services Research Unit Maes, Michael; Chulalongkorn University, Department of Psychiatry Younger, Jarred; University of Alabama at Birmingham Feliu-Soler, Albert; Autonomous University of Barcelona, Department of Clinical and Health Psychology Rozadilla-Sacanell, Antoni; Institut de Recerca Sant Joan de Déu, Department of Rheumatology - Parc Sanitari Sant Joan de Déu Luciano, Juan; Parc Sanitari Sant Joan de Déu, Teaching, Research & Innovation Unit; Universitat Autònoma de Barcelona, Clinical and Health Psychology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Health economics, Pharmacology and therapeutics, Public health
Keywords:	PAIN MANAGEMENT, HEALTH ECONOMICS, Clinical trials <

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3 **Study protocol for a randomised, double-blinded, placebo-controlled phase III trial**  
4 **examining the add-on efficacy, cost-utility and neurobiological effects of low-dose**  
5 **naltrexone (LDN) in patients with fibromyalgia (INNOVA study)**  
6  
7  
8  
9

10  
11  
12 Ariadna Colomer-Carbonell<sup>1,2,3\*</sup>. ORCID: 0000-0001-8923-6316

13  
14 Juan P. Sanabria-Mazo<sup>1,2,3\*</sup>. ORCID: 0000-0003-1688-435X

15  
16 Halbert Hernández-Negrín<sup>4\*</sup>. ORCID: 0000-0002-9992-9148

17  
18 Xavier Borràs<sup>3</sup>. ORCID: 0000-0003-3972-1385

19  
20 Carlos Suso-Ribera<sup>5,6</sup>. ORCID: 0000-0002-2655-1017

21  
22 Azucena García-Palacios<sup>5,6</sup>. ORCID: 0000-0001-9250-8714

23  
24 Jordi Muchart<sup>7</sup>. ORCID: 0000-0003-4702-5072

25  
26 Josep Munuera<sup>7</sup>. ORCID: 0000-0001-5154-1796

27  
28 Francesco D'Amico<sup>8</sup>. ORCID: 0000-0001-5289-9300

29  
30 Michael Maes<sup>9</sup>. ORCID: 0000-0002-2012-871X

31  
32 Jarred W. Younger<sup>10</sup>. ORCID: 0000-0003-3616-9919

33  
34 Albert Feliu-Soler<sup>11\*\*</sup>. ORCID: 0000-0003-2810-7670

35  
36 Antoni Rozadilla-Sacanell<sup>1,12,13\*\*</sup>. ORCID: 0000-0002-7555-189X

37  
38 Juan V. Luciano<sup>1,2,11\*\*</sup>. ORCID: 0000-0003-0750-1599  
39  
40  
41  
42  
43  
44  
45  
46

47 **Author affiliations**

48  
49 <sup>1</sup>Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain

50  
51 <sup>2</sup>Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat,  
52 Spain  
53

54  
55 <sup>3</sup>Department of Basics, Developmental and Educational Psychology, Autonomous University  
56 of Barcelona, Cerdanyola del Vallès, Spain  
57  
58  
59  
60

1  
2  
3 <sup>4</sup>Hospital Universitario Arnaldo Milián Castro & Universidad de Ciencias Médicas de Villa  
4 Clara, Santa Clara, Cuba.

5  
6  
7  
8 <sup>5</sup>Department of Basic and Clinical Psychology and Psychobiology, University Jaume I,  
9 Castellon de la Plana, Spain

10  
11  
12 <sup>6</sup>Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn),  
13 Institute of Health Carlos III, Madrid, Spain

14  
15  
16  
17 <sup>7</sup>Diagnostic Imaging Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain

18  
19  
20 <sup>8</sup>Personal Social Services Research Unit, London School of Economics and Political Science,  
21 London, UK

22  
23  
24 <sup>9</sup>Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand

25  
26  
27 <sup>10</sup>Department of Psychology, University of Alabama at Birmingham, Birmingham, USA

28  
29  
30 <sup>11</sup>Department of Clinical and Health Psychology, Autonomous University of Barcelona,  
31 Cerdanyola del Vallès, Spain

32  
33  
34 <sup>12</sup> Rheumatology Service, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat, Spain

35  
36  
37 <sup>13</sup>School of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain

38  
39  
40  
41 \*AC-C, JPS-M and HH-N are joint first authors.

42  
43  
44 \*\*AF-S, AR-S and JVL are joint senior authors.

## 45 46 47 48 49 50 51 52 **Correspondence**

53  
54 Juan V. Luciano. Department of Clinical & Health Psychology, Autonomous University of  
55 Barcelona. 08193, Cerdanyola del Vallès, Spain. E-mail: [juanvicente.luciano@uab.cat](mailto:juanvicente.luciano@uab.cat)

## ABSTRACT

**Introduction.** There is evidence that low-dose naltrexone (LDN; < 5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility, and neurobiological effects of LDN for reducing pain in FMS patients, with a one-year follow-up.

**Methods and analysis.** A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3-months (T1), 6-months (T2), and 12-months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (e.g., pain intensity, fatigue, and sleep disturbance), and side effects via ecological momentary assessment (EMA) through the Pain Monitor app® during the first three months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with magnetic resonance imaging (MRI) at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitization. Inflammatory biomarkers in serum will also be measured.

**Ethics and dissemination.** This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media, and community engagement activities.

**Trial registration number:** ClinicalTrials.gov (NCT04739995)



### Strengths and limitations of this study

- This is thought to be the first randomised, double-blinded, placebo-controlled phase III trial to assess the efficacy, safety, cost-utility, and neurobiological effects of low-dose naltrexone (LDN) for reducing pain in patients with fibromyalgia syndrome.
- The INNOVA protocol combines mobile-technology-based ecological momentary assessment and assessment with classical legacy measures to obtain more precise information on the dynamics of the assessed primary and secondary outcomes.
- This study will include immune and neuroimaging biomarkers in order to explore the neurobiological underpinnings of LDN.
- Challenges of the RCT include the long follow-up period (one year) and potential measurement burden that takes the risk of high dropout rate.

## INTRODUCTION

### **Fibromyalgia: definition, prevalence, and pharmaceutical indications**

Fibromyalgia syndrome (FMS) is a chronic condition of unknown origin that is characterised by generalised musculoskeletal pain, fatigue, stiffness, cognitive problems, sleep disturbances, and malaise.<sup>1,2</sup> This syndrome is highly prevalent in the general population (2.7% worldwide).<sup>3</sup> Around 6% of adult patients who visit their general practitioner, and between 10-20% of those who visit rheumatology services, have FMS.<sup>2</sup> In 2007, the U.S. Food and Drug Administration approved pregabalin as the first drug indicated for the treatment of FMS, and later approved duloxetine and milnacipran for this indication. However, the European regulatory authorities rejected the indication of these three drugs in the treatment of FMS given the small effect sizes in various studies and the associated adverse effects.<sup>4-6</sup>

### **Pathogenesis of FMS**

Although the etiological factors of FMS are not known, the primary hypothesis of the pathogenesis of this syndrome highlights the role of the central nervous system in the amplification of pain perception as well as in the development of comorbid symptoms such as sleep-related problems, fatigue, cognitive difficulties, and emotional distress.<sup>1,7,8</sup> Structural brain alterations have also been found in patients with FMS. For example, lower volumes of grey matter have been observed in areas associated with the processing of stress (e.g., parahippocampal gyrus) and pain (e.g., anterior cingulate cortex, insula, prefrontal cortex, and primary and secondary somatosensory cortices).<sup>7</sup> Functional MRI alterations been associated with self-reported pain intensity. Brain activity exhibited greater connectivity between different pain-processing areas (e.g., insula and secondary somatosensory cortex), the default-model network in persons with FMS, as well as in the association between these areas and the pain levels reported by patients and the right executive attention network.<sup>9</sup>

1  
2  
3 Altered functional connectivity has also been reported among various pain-inhibiting  
4 areas.<sup>10</sup> Some studies have reported reduced levels of neurotransmitters involved in the  
5 regulation of the descending analgesic response (serotonin and noradrenaline) and increased  
6 levels of glutamate (Glu) and substance P in people with FMS.<sup>11-14</sup> For example, high levels of  
7 Glu have been reported in the posterior insula, posterior cingulate cortex and prefrontal  
8 ventrolateral cortex of patients with FMS when compared to healthy controls<sup>15-19</sup>.

17  
18 Activation of the microglia could be a contributing factor to the alteration of glutamate  
19 neurotransmission in FMS.<sup>20,21</sup> The microglia is normally found in a state of rest but it is  
20 activated by a wide range of stimuli such as cell death, peripheral inflammation, chronic stress  
21 and infections.<sup>22</sup> Once activated, microglia release pro-inflammatory agents such as cytokines,  
22 excitatory amino acids and nitric oxide.<sup>23</sup> These inflammatory factors across multiple neural  
23 pathways can induce hyperalgesia, fatigue, depression and other symptoms which are known  
24 collectively as “cytokine induced sickness behavior”.<sup>24,25</sup> Microglia activation might trigger a  
25 series of actions that lead to an increase in Glu that ultimately results in synaptic dysfunction.<sup>26</sup>  
26 A recent study using Positron Emission Tomography<sup>27</sup> of translocator protein revealed a  
27 widespread cortical glial activation in patients with FMS, which gives support to the role of  
28 neuroinflammation in the aetiology of FMS. In addition, there is evidence that chronic stress  
29 facilitates the “priming” and exaggerated activation of the microglia.<sup>28</sup>

35  
36 Although FMS is not considered a classic inflammatory disease, there is extensive  
37 evidence that immune pathways play a significant role in the pathogenesis and maintenance of  
38 the syndrome. Cytokines play a key role in inflammatory response and in boosting the  
39 nociceptive response due to their sensitization actions, both on a peripheral and central level.<sup>29-</sup>  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Although FMS is not considered a classic inflammatory disease, there is extensive evidence that immune pathways play a significant role in the pathogenesis and maintenance of the syndrome. Cytokines play a key role in inflammatory response and in boosting the nociceptive response due to their sensitization actions, both on a peripheral and central level.<sup>29-</sup>  
<sup>32</sup> Thus, there is evidence that FMS involves an imbalance in pro-inflammatory (e.g. IL-1, IL-6, IL-17A, and TNF- $\alpha$ ) and anti-inflammatory (e.g. IL-4 and IL-10) levels of cytokines that could lead to a low-intensity, chronic state of inflammation. Bäckryd and colleagues<sup>30</sup>

1  
2  
3 identified both neuroinflammation and systemic inflammation by evaluating levels of a broad  
4 panel of cytokines and chemokines in cerebrospinal fluid and plasma.  
5  
6

### 7 8 **Low-dose naltrexone (LDN): A promising treatment for FMS** 9

10  
11 Naltrexone is an opioid antagonist medication used to treat opioid and alcohol  
12 dependency. The drug blocks mu-opioid receptors, the delta-opioid receptors and, to a lesser  
13 extent, the kappa-opioid receptors. There is promising evidence to suggest that naltrexone  
14 administered in low doses (i.e., low-dose naltrexone; < 5 mg/day) is effective in the  
15 management of some pathologies which present with altered immune pathways, such as  
16 Crohn's disease, multiple sclerosis, or FMS.<sup>33,34</sup> The immune-regulatory effect of LDN seems  
17 to be driven through the inhibition of the Toll-like receptor 4 (TLR-4) activity expressed in the  
18 membrane of various immune system cells (e.g., microglia and macrophages).<sup>33</sup> Moreover, due  
19 to a “rebound effect”, LDN could exert an analgesic effect that strengthens the endogenous  
20 opioid pain inhibitory system. According to this hypothesis, the low-intensity and intermittent  
21 blockade of the opioid receptors generated by LDN induces a compensatory mechanism that  
22 facilitates an increase in the production of endogenous opioids and greater sensitivity of the  
23 system to their effects.<sup>33,34</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 To date, the effects of LDN in patients with FMS have only been evaluated through  
42 crossover pilot studies that have yielded preliminary results. In the first study conducted with  
43 LDN in FMS, significant reductions in pain, stress, and fatigue levels were observed.<sup>35</sup> In a  
44 subsequent study, significant improvements in daily pain, satisfaction with life and mood were  
45 also observed.<sup>36</sup> In another crossover investigation, the pre and post changes in the levels of  
46 plasma cytokines were evaluated over eight weeks. Significant reductions in a wide range of  
47 immune biomarkers were obtained (e.g., IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, IL-10, IL-17A, and TNF-  
48  $\alpha$ ), together with a reduction in the pain levels and the severity of FMS symptoms.<sup>37</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 While acknowledging the contribution of past studies into the field, these have included  
4 small sample sizes (n= 8 to 31 participants) and crossover designs. Therefore, a single-site,  
5 prospective, randomised, double-blinded, placebo-controlled study (RCT) with a sufficiently  
6 powered sample is presented here to conduct a methodologically robust investigation into the  
7 role of LDN in FMS. Specifically, the main objective of the INNOVA study is to evaluate the  
8 efficacy, safety, and cost-utility, and neurobiological effects of LDN to reduce pain in FMS.  
9  
10 There is currently no gold standard pharmacological treatment for pain reduction in persons  
11 with FMS. Therefore, in the present study, placebo will be used instead of another drug in the  
12 control group.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **METHODS AND ANALYSIS**

### 25 **Trial design**

26  
27 The randomised controlled trial (RCT) protocol has been developed following the  
28 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)<sup>38</sup>. In addition,  
29 the RCT was approved by European Union Drug Regulating Authorities Clinical Trials  
30 (EudraCT; 2021-002534-16). For reporting purposes, we will follow the guidelines of the  
31 Consolidated Standards of Reporting Trials (CONSORT)<sup>39</sup> and the Consolidated Health  
32 Economic Evaluation Reporting Standards (CHEERS) statement.<sup>40</sup> INNOVA is a 12-month  
33 double-blind RCT with two arms: LDN vs. Placebo. LDN will be considered an add-on  
34 treatment to the usual care provided in the Spanish National Health System for FMS. For  
35 transparency and analytical reproducibility purposes, the dataset and data coding will be  
36 deposited in the Open Science Framework.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Sample size**

53  
54 There are no previous RCTs about the efficacy of LDN for FMS, therefore, we  
55 estimated the sample size taking into account a previous LDN crossover study<sup>36</sup> that had used  
56 self-reported pain as main outcome (the effect size was  $d = .99$ ). Thus, with a sample of 60  
57  
58  
59  
60

1  
2  
3 participants per arm, we aim to detect between-group differences with a significance level of  
4  
5 5% and a power of 80%. Allowing for a potential attrition rate of 20%, our final sample size is  
6  
7 60 participants per group. For the analysis of biomarkers (involving 50% of the sample), an  
8  
9 initial sample size of 30 patients per arm is considered sufficient according to previous  
10  
11 studies.<sup>37,41</sup>

## 12 13 14 15 **Eligibility criteria**

16  
17 *General selection criteria.* All participants will meet the following inclusion criteria:  
18  
19 women between 18-70 years; diagnoses of FMS according to American College of  
20  
21 Rheumatology 2016 criteria<sup>42</sup> by a rheumatologist; pain intensity ranked  $\geq 4$  out of 10 on a 10-  
22  
23 point numerical rating scale in the past week; fluent in Spanish; provision of written informed  
24  
25 consent; stable pharmacological treatment in the last two months; and having a smartphone  
26  
27 with android operating system for Ecological Momentary Assessment (EMA). Potential  
28  
29 participants will be excluded according to the following exclusion criteria: treatment with  
30  
31 naltrexone, opioids, anticoagulants, or central anti-hypertensives in the last 3 months; diagnosis  
32  
33 of severe medical/psychiatric disorders (e.g., cancer, haematological diseases, abnormal  
34  
35 hepatic/liver function, renal failure, suicide ideation, psychotic disorder); pregnant (or planning  
36  
37 to become pregnant during the study period) or breastfeeding; known allergy to naltrexone,  
38  
39 naloxone or excipients; currently participating in other RCTs; ongoing litigation related to  
40  
41 FMS.  
42  
43  
44  
45  
46

47  
48 *Additional selection criteria for the biomarkers and neuroimaging sub-study (50% of*  
49  
50 *patients in each study arm).* All participants will meet the following inclusion criteria:  
51  
52 right-handed (for the neuroimaging tests); and no comorbid rheumatologic conditions (e.g.,  
53  
54 rheumatoid arthritis, lupus). Potential participants will be excluded according to the following  
55  
56 exclusion criteria: fever ( $> 38^{\circ}\text{C}$ ); infection in the last two weeks; vaccination in the last month;  
57  
58 taking cortisone or anti-cytokine therapy; needle phobia or claustrophobia, metal implants or  
59  
60

1  
2  
3 pacemakers; body mass index  $\geq 36$  kg/m<sup>2</sup>; smoking over 5 cigarettes/day; presence of acute  
4  
5 pain (e.g, headache or back pain) unrelated to FMS on the day of the scan.  
6  
7

### 8 **Recruitment strategy, procedure and randomisation**

9

10 Patients diagnosed with FMS with an appointment at the Rheumatology Service of Parc  
11 Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) will be invited to participate in the  
12 study and will be asked to attend a screening evaluation with a research assistant and a clinician.  
13  
14 Once the informed consent is obtained, the clinician will review the study selection criteria to  
15 confirm eligibility. The week after, a face-to-face assessment (T0) including clinical history  
16 and variables related to the use of services will be conducted with those patients meeting all  
17 the eligibility criteria. Only the participants that are included in the biomarkers sub-study will  
18 require an additional blood extraction and neuroimaging scan, which will be performed in the  
19 following 3-5 days. Participants will be given a sealed envelope with an identifying code which  
20 they will have to take to the pharmacy service. There, they will be given the dose of the  
21 corresponding drug (according to the randomisation) for the first 3 months (90 tablets). As  
22 shown in the patients' flow chart (Figure 1), further in-person evaluations will be performed at  
23 3 months (T1), 6 months (T2), and 12 months (T3). Neurobiological variables will be obtained  
24 at T1 using the same protocol as in the baseline assessment (T0).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Participants will be asked to abstain from taking any analgesic or anti-inflammatory  
43 drug in the 72h prior to the blood extractions/scans. All patients, including those who do not  
44 participate in the biomarker sub-study, shall be subjected to a blood test at baseline. Participants  
45 will return to the pharmacy service every 3 months and will be given the assigned amount of  
46 LDN/placebo for the following 3 months (approximately 90 tablets). Unconsumed tablets will  
47 be returned for treatment adherence monitoring. The randomisation to conditions will be  
48 conducted by a biostatistician from the Clinical Trials Unit of Fundació Sant Joan de Déu who  
49 has no involvement in the eligibility screening, enrolment, and treatment processes. The  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 computer-generated randomisation will apply a permuted block design to ensure that the study  
4 arms are balanced taking the biomarkers sub-study eligibility criteria into account. As this is a  
5 double-blind RCT, neither the patient nor the evaluator or the clinician will know to which  
6 treatment arm each patient has been assigned. Only the clinical trial pharmacist who stores and  
7 delivers capsules, but is not involved in patient care, will know the allocation.  
8  
9  
10  
11  
12  
13

14  
15 Figure 1

### 16 17 **Data management, central monitoring and audit**

18  
19 The clinical data entry, data management, and central monitoring will be performed  
20 with REDCap®. An independent Clinical Research Organization (CRO) will be responsible  
21 for overseeing the intra-study data sharing and storing process. Any modifications in the study  
22 protocol will be communicated to the CRO.  
23  
24  
25  
26  
27

### 28 29 **Treatments**

30  
31 **Low-dose naltrexone (LDN).** The intervention group will take one 4.5 mg naltrexone  
32 tablet (lactose-free) daily for 12 months before going to sleep.  
33  
34

35  
36 **Placebo.** The control group will take the placebo daily for 12 months (a film-coated  
37 tablet identical to the LDN and filled with a lactose-free filler). For the control arm, the same  
38 guidelines will be followed.  
39  
40  
41

42  
43 In order to maintain the external validity of the study and for ethical reasons, the study  
44 participants' active treatments will be unchanged by this clinical trial. In Spain, chronic pain  
45 management is mainly managed by general practitioners in regular consultations. These  
46 generally consist of face-to-face appointments with a duration of 5-10 minutes in which the  
47 clinicians monitor the physical and, ideally, the emotional status of the patient. General  
48 practitioners usually provide advice prescribe pharmacotherapy (pain killers, hypnotics,  
49 antidepressants, etc.) or refer patients to pain units in tertiary hospitals when more specialised  
50 pain management procedures are required. The frequency of consultations is based on the type  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 of disease and its severity. In this study, usual care will be the same as in routine daily practice,  
4  
5 without any modifications. In addition, participants will be allowed to withdraw from this study  
6  
7 for any reason at any time without detriment to the provision or quality of their usual care. If a  
8  
9 severe adverse event occurs, unblinding will be possible and study participation will be  
10  
11 discontinued. If the adverse effects are tolerable, the treatment will be administered until the  
12  
13 end of the study. All these events will be recorded and reported at the end of the study.  
14  
15

### 16 17 **Study measures**

18  
19 All participants will be assessed with a computer-administered battery of measures  
20  
21 using the REDCap® software (see Table 1).  
22  
23

24  
25 Table 1

### 26 27 **Measures for sociodemographic characteristics, clinical features, and screening**

28  
29 A *sociodemographic questionnaire* will be used to obtain information about the  
30  
31 following variables: gender, date of birth, marital status, living arrangements, educational level,  
32  
33 income level, and employment status.  
34  
35

36  
37 The *Clinical data* interview will be used to collect information about history and  
38  
39 duration of FMS symptoms, as well as family history of medical/mental illness. Information  
40  
41 regarding comorbidity with other diagnosed physical-psychiatric conditions and the type and  
42  
43 dose of current drugs will be checked from medical records.  
44

45  
46 The *Fibromyalgia Survey Diagnostic Criteria* (FSDC)<sup>43,44</sup> is a 6-item self-report  
47  
48 measure of the core FMS symptoms according to the latest revision of the American College  
49  
50 of Rheumatology (ACR) 2016 criteria.<sup>42</sup> It includes two subscales: the Widespread Pain Index,  
51  
52 which is used to identify the presence of pain in 19 body areas in the last week, and the  
53  
54 Symptom Severity Scale, in which the three major FMS symptoms (fatigue, “fibrofog” and  
55  
56 waking up tired) are assessed along with three additional symptoms (pain in the lower stomach,  
57  
58  
59  
60

1  
2  
3 depression and headache). A total score is obtained by adding the two subscales. This total  
4  
5 score ranges from 0 to 31, where higher values indicate greater FMS severity.  
6  
7

### 8 **Primary outcome measure**

9

10 The *Numeric Rating Scale* (NRS)<sup>45</sup> is a unidimensional measure of pain intensity  
11  
12 mainly used for adults. The most frequently used version is an 11-point numeric scale (a  
13  
14 horizontal bar or line) scored from 0 (“no pain”) to 10 (“worst pain imaginable”). Time frames  
15  
16 vary between studies. In the present study, respondents will be asked to report average pain  
17  
18 intensity over the last week.  
19  
20  
21

### 22 **Secondary outcome measures**

23

24 The *Revised Fibromyalgia Impact Questionnaire* (FIQR)<sup>46</sup> includes 21 items that are  
25  
26 answered on a 0 to 10 numerical scale in which higher scores indicate greater functional  
27  
28 impairment. The questionnaire asks about the previous seven days. The items are distributed  
29  
30 into three domains: physical impairment, overall impact, and severity of symptoms (i.e., pain,  
31  
32 energy, stiffness, sleep quality, depression, memory issues, anxiety, pain to the touch, balance  
33  
34 problems and increased sensitivity to noises, lights, smells, or temperatures). A total score is  
35  
36 obtained by summing the three subscale scores. This can range from 0 to 100. Higher scores  
37  
38 indicate greater impairment. The Spanish version of the FIQR and has obtained high internal  
39  
40 consistency estimates ( $\alpha = .91 - .95$ ), adequate test-retest reliability indices ( $r = .82$ ), and good  
41  
42 construct validity.<sup>47</sup>  
43  
44  
45  
46

47 The *Depression Anxiety Stress Scales-21* (DASS-21)<sup>48</sup> is a self-report scale developed  
48  
49 to discriminate between features of depression (anhedonia/low positive affect), anxiety  
50  
51 (physical arousal) and stress (psychological tension/agitation) in clinical and non-clinical  
52  
53 samples. The DASS has been validated in patients with FMS.<sup>49</sup> Responders are required to  
54  
55 indicate the presence of a symptom over the previous week. Each item is scored from 0 (“did  
56  
57 not apply to me at all over the last week”) to 3 (“applied to me very much or most of the time  
58  
59  
60

1  
2  
3 over the past week”). There are seven items on each of the three subscales: depression, anxiety,  
4 and stress. Therefore, total scores in each scale can range from 0 to 21. Higher scores indicate  
5 more severe levels of depression, anxiety and stress. The Spanish version showed adequate  
6 internal consistency for depression ( $\alpha = .84$ ), anxiety ( $\alpha = .70$ ) and stress ( $\alpha = .82$ ).<sup>50</sup>  
7  
8  
9

10  
11  
12 The *Multidimensional Inventory of Subjective Cognitive Impairment* (MISCI)<sup>51</sup> is a  
13 10-item self-report measure of subjective cognitive dysfunction (i.e., “fibrofog”) in FMS.  
14 Each item is scored from 1 (“never”) to 5 (“very often”) and the total score ranges from 10 to  
15 50. Lower scores indicate higher cognitive dysfunction. The MISCI showed excellent internal  
16 reliability, low ceiling/floor effects and good convergent validity with a similar measure. The  
17 Spanish version of the MISCI had sound psychometric properties ( $\alpha = .91$  and ICC = .88).<sup>52</sup>  
18  
19  
20  
21  
22  
23  
24  
25

26 The *World Health Organization Disability Assessment Schedule 2.0* (WHODAS  
27 2.0)<sup>53</sup> is a 12-item self-report measure of the level of difficulty experienced taking into  
28 consideration how they usually do the activity. This includes the use of any devices to assist  
29 them and/or the help of a person. In each item, individuals estimate the magnitude of the  
30 disability during the previous 30 days using a five-point scale scored from 1 (none) to 5  
31 (extreme/cannot do). The total score ranges from 0 to 100. Higher scores reflect greater  
32 disability. The 12-item WHODAS 2.0 has sound psychometric properties in patients with  
33 FMS.<sup>54</sup>  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The *Generalized Anxiety Disorder 7-item scale* (GAD-7)<sup>55</sup> is a 7-item self-report  
46 measure of pathological worry. Each item is scored from 0 (“not at all”) to 3 (“nearly every  
47 day”). The total score ranges from 0 to 21, where higher scores reflecting greater anxiety  
48 symptoms. The GAD-7 has sound psychometric properties ( $\alpha = .92$  and ICC = .83) in patients  
49 with FMS in previous studies.<sup>56</sup>  
50  
51  
52  
53  
54  
55

## 56 **Other measures**

57  
58  
59  
60

1  
2  
3 The *ACTION AE* is a *reporting checklist* used to measure safety and benefit-risk of  
4 a clinical trial.<sup>57</sup> The Safety and Benefit-Risk Reporting and Evaluation (SABRRE) Working  
5 Group of the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations, Innovations,  
6 Opportunities, and Networks (ACTION; <http://www.action.org>) public-private partnership  
7 with the FDA developed an adverse events (AE) reporting checklist that will be used in the  
8 present study.  
9  
10  
11  
12  
13  
14  
15  
16

17 The *EuroQoL* (version EQ-5D-5L)<sup>58</sup> is a health-related quality of life questionnaire  
18 that consists of two parts. In the first one, the individual's difficulties concerning mobility,  
19 self-care, pain/discomfort and anxiety/depression are evaluated. In the second part, the  
20 perceived health is assessed by means of a Visual Analogue Scale ranging from 0 to 100. The  
21 EQ-5D-5L scores will be used to calculate the Quality-Adjusted Life Years (QALYs) during  
22 the follow-up period by adjusting the duration of time affected by the health outcome by the  
23 value of the utility.  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The *Client Service Receipt Inventory* (CSRI)<sup>59</sup> is a self-report tool used to collect  
34 retrospective data on medication consumption and service receipt. Patients are asked to bring  
35 their daily medication prescriptions and information about pain-related drugs (analgesics,  
36 anti-inflammatories, opioids, muscle relaxants, antidepressants, etc.) is recorded. This  
37 includes the name of the drug, the dosage, total number of prescription days and daily dosage  
38 consumed. Concerning service receipt, patients are asked about the total appointments for  
39 accident and emergency services, total number of general inpatient hospital admissions,  
40 number of diagnostic tests administered and total appointments with healthcare professionals  
41 for pain management (family physicians, nurses, social workers, psychologists, psychiatrists,  
42 group psychotherapy and other community healthcare professionals). The CSRI will be  
43 administered on two occasions: at baseline and at 12-month follow-up, both referring to the  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 previous 12 months. Medical records will be checked to verify the accuracy of the collected  
4  
5 data.  
6  
7

8 The *Patient Global Impression of Change* (PGIC) measures meaningful change in  
9  
10 overall status and the *Pain Specific Impression of Change* (PSIC)<sup>60</sup> measures the perception  
11  
12 of pain improvement. The most frequently used scale is a 7-point numerical scale scored from  
13  
14 1= “much better”) to 7= “much worse”).  
15  
16

### 17 **Ecological momentary assessment (EMA)**

18  
19 Pain intensity and other pain-related variables (e.g., depressive-anxious symptoms and  
20  
21 activity level) can fluctuate during the day and across days depending on personal and  
22  
23 environmental factors. Collecting self-reported data prospectively and closer in time to its  
24  
25 occurrence substantially improves the accuracy, reliability and quality of data. EMA has been  
26  
27 successfully performed in patients with a variety of physical and mental problems.<sup>61,62</sup> There  
28  
29 is growing evidence indicating that well-designed smartphone apps can be easy to use and well-  
30  
31 tolerated even in relatively old pain populations, with compliance rates as high as 85%.<sup>61</sup> In  
32  
33 this RCT, we will use the Pain Monitor® (Monitor de Dolor, by its Spanish name) app<sup>63</sup> to  
34  
35 assess a wide range of variables (see items in Table 2) twice a day (once in the morning and  
36  
37 once in the evening, at convenient times along the week) during 120 days. The app and the data  
38  
39 will be stored on different servers with different domain names and connected locally only (the  
40  
41 server containing the data does not have Internet access). According to a recent meta-analysis,<sup>64</sup>  
42  
43 EMA-completion rates are higher among elderly patients compared to younger patients.  
44  
45 Considering that the majority of FMS patients in our study are not expected to be young and  
46  
47 that the EMA item battery does not require a long response time (< 1 min.), it is expected not  
48  
49 to place an excessive burden on participants.  
50  
51  
52  
53  
54  
55

56 Table 2  
57  
58  
59  
60

### Inflammatory biomarkers

After obtaining the blood sample, it will be allowed to coagulate for a minimum of 30 minutes at room temperature. It will then be centrifuged for 10 minutes at 1000g. The resulting serum will be stored at -80° C during the same morning of extraction until it is ready to be analysed. All samples (at T0 and T1) will be analysed in a single analytical batch to reduce inter-assay variability (approx. 15%). The serum levels of IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, sIL-6r, sgp130, CXCL-8, IL-10, IL-17, TNF- $\alpha$ , and high-sensitivity C-reactive protein (hs-CRP) will be evaluated.<sup>29</sup> For the quantification of the cytokines, the Milliplex® reagents from the company MerckMillipore® will be used and analysed using a Luminex® platform. The high sensitivity multiplex kit will be used: Human High Sensitivity T Cell, catalogue number: HSTCMAG28SPMX11, adapted to the aforementioned cytokines. The hs-PCR will be quantified using turbidimetry in an Olympus AU5400 auto-analyser. These biomarkers will only be evaluated at baseline (T0) and 3-months (T1) for the following reasons: (a) there is evidence of significant inflammatory changes at 8 weeks with LDN;<sup>37</sup> (b) this results in lower risk of dropout (vs. evaluating them at 6 or 12 months); (c) conducting at least two measures allows to use the change between baseline and 3-months as a mediator of long-term clinical changes; and (d) budget constraints.

### Neuroimaging

The scans (protocol duration: approximately 30 minutes) will be performed in a Phillips Ingenia 3T MRI scanner with a 32-channel head coil at Hospital Sant Joan de Déu (Esplugues de Llobregat, Spain). To examine cingulate, insular, amygdalar, occipital, angular, parahippocampal, and prefrontal gray matter volume, we will use voxel-based morphometry (VBM). We will also use surface-based morphometry (with FreeSurfer calculation of cortical thickness, surface area, and local gyrification index) for examining cortical abnormalities. Additionally, glutamate, glutamine, myo-inositol, N-acetylaspartate, choline, and creatine

1  
2  
3 (and creatinine ratios) levels will be analysed using magnetic resonance spectroscopy.  
4  
5 Specifically, we will conduct the following processing for the regions of interest according to  
6  
7 the corresponding hypotheses. For VBM, we will apply a bias field correction, tissue  
8  
9 segmentation with SPM12, normalization with DARTEL, modulation, and smoothing. We  
10  
11 will use both unmodulated and modulated grey matter images to convey complementary  
12  
13 volumetric information. We will use FreeSurfer ENIGMA pipelines to perform the VBM. In  
14  
15 addition, we will quantify metabolites concentrations using LCModel (v6.3-1J). We will only  
16  
17 include high-quality spectra, defined as signal-to-noise ratio > 15, Cramer-Rao lower bounds  
18  
19 < 15%, and full width at half maximum of metabolites < .07. The spectroscopy analysis will  
20  
21 account for the effects of cerebrospinal fluid and grey matter within the voxel, and inter-  
22  
23 individual differences in cortical grey matter.  
24  
25  
26  
27

### 28 **Statistical analysis**

29  
30  
31 The main analysis will compare the effect of LDN vs. placebo on the primary outcome  
32  
33 (pain intensity at T1). Data analyses will be performed following an intention-to-treat (ITT)  
34  
35 plan. Then, we will compute analysis of the primary outcome (at T2 and T3) and analysis of  
36  
37 the secondary outcomes at T1, T2 and T3. Linear mixed models will be created using the  
38  
39 restricted maximum likelihood method for the estimation of parameters. The effect sizes will  
40  
41 be calculated according to Cohen's *d*. An interim analysis is planned at T1 once 50% of the  
42  
43 total sample has been evaluated. A 5% significance level will be used in all two-tailed tests,  
44  
45 applying the Benjamini-Hochberg correction for multiple comparisons. Additionally, to make  
46  
47 the findings from our study clinically meaningful, the number needed to treat will be reported.  
48  
49 For this analysis, we will dichotomise participants into responders or non-responders using two  
50  
51 different cut-off criteria in compliance with the IMMPACT recommendations:<sup>45</sup> At least 50%  
52  
53 pain relief over baseline (substantial benefit) or 30% or more pain relief (moderate benefit).  
54  
55 For these analyses, we will use SPSS v26 (IBM Corp, Armonk, NY, USA).  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Regarding EMA, a recent recommended approach is "network analysis". There has been burgeoning interest in conceptualizing chronic pain as a network of interacting symptoms and psychobiological processes.<sup>65</sup> Network analysis will offer us a good chance to quantify and visualize relationships between pain intensity and pain-related variables (e.g., depression, anxiety, fatigue, sleep disturbance). We will estimate temporal networks by means of vector autoregression techniques;<sup>66</sup> These "temporal networks", would indicate potential causality with one or more variables preceding one or more variables in time. Network analysis will be performed with the free statistical software JASP.<sup>67</sup>

In economic evaluation, it is important to calculate the relationship between the costs of each treatment and its consequences in the form of QALYs, an index measure designed to assess both quantity of life (years) and health-related quality of life. A year lived with the maximum quality of life would be transformed into 1 QALY; a year lived with half the maximum quality of life would be transformed into 1/2 QALY. This relative value is called the incremental cost-utility ratio (ICUR) and it expresses the relationship between the costs and the effects of one option compared to another. The QALYs obtained in the 12 months after the treatment onset will be calculated by the area under the curve. The direct costs will be calculated by adding together the costs derived from the medication and the use of the health services. The cost of medications will be calculated by multiplying the price per milligram by the total daily dose consumed (in milligrams) and the number of days that the treatment is received. The cost arising from the use of the health services (primary care, specialist and accident and emergency consultations, and hospital admissions) will be obtained from the clinical electronic records (<http://www.oblikue.com/en/esalud.html>). The indirect costs will be calculated based on the days off work, which will be multiplied by the official minimum wage during the study period. The effect of the treatments will be estimated using ordinary least squares multivariate regression, adjusting for the baseline differences between groups. In order



1  
2  
3 to manage uncertainty in the sampling distribution of the ICUR, non-parametric bootstrapping  
4 will be applied, with 1000 replications in each comparison. Cost-utility analyses will be  
5  
6 conducted with STATA v16.0 (StataCorp, College Station, TX, USA).  
7  
8  
9

### 10 **Patient and public involvement**

11  
12 Patients and the public will not be involved in the design, conduct, reporting, or  
13 dissemination of our research.  
14  
15

### 16 **ETHICS AND DISSEMINATION**

17  
18 All procedures performed in this study will be in accordance with the 1964 Helsinki  
19 declaration and its last amendments (7<sup>th</sup> revision, adopted by the 64<sup>th</sup> World Medical  
20 Association General Assembly, Fortaleza, Brazil). Signed informed consent will be obtained  
21 from all patients once they have been informed of the study procedures, potential risks, and  
22 their right to withdraw at any time from the RCT. The FSJD Ethics Committee Board evaluated  
23 and approved the study protocol in June 2021 (PIC-178-19). Only the principal investigators  
24 (ARS and JVL) will have full access to the final trial dataset. Modifications in the study  
25 protocol will be reported to the FSJD Ethics Committee Board as well as the independent CRO.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Once the RCT is completed, we will publish our results in international peer-reviewed  
39 biomedical journals and present them at national and international conferences. Authorship  
40 will be assigned in accordance with the International Committee of Medical Journal Editors  
41 guidance. In addition, we will send participating patients a short report of our findings. A copy  
42 of the report will also be sent to Institute of Health Carlos III (main funding body). The  
43 principal investigators will organize an end-of-study seminar. The main objective of this  
44 activity will be to share the study findings with stakeholders to discuss how to maximize uptake  
45 of the findings in patient treatment and clinical practice, and to determine future research  
46 directions.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

As far as we know, no RCT has been published about the efficacy, safety, cost-utility, and neurobiological underpinnings of LDN in patients with FMS. This manuscript presents the design and rationale of a randomised, double-blinded, placebo-controlled phase III study, which is a powerful design to assess the efficacy of LDN. We have decided to administer 4.5 mg/day of LDN in this RCT because this dose seems to provide an optimal balance between significant analgesic efficacy and minimal side effects (nausea, sleep disturbance, nightmares, etc.) according to a recent study.<sup>68</sup>

Our findings using this design in conjunction with those that will be obtained in another ongoing RCT that is being carried out in Denmark (The FINAL study)<sup>69</sup> may facilitate the approval of the first drug indicated for the treatment of FMS in Europe. The FINAL study is an ongoing single-centre, randomised, double-blinded, placebo-controlled trial that is being carried out in Odense (Denmark). A total of 100 women between 18–64 years-old with FMS will take either LDN or placebo for three months. Besides self-report measures, Danish researchers will also examine the levels of pro- and anti-inflammatory cytokines. If our respective findings strongly differ in efficacy or safety, we might analyse which factors can account for the divergence and plan a multi-country confirmatory trial with an agreed design and methodology. As pointed out by Kim and Fishman<sup>70</sup>, a common problem with a generic, compounded medication is the lack of commercial support for research. To begin studies such as INNOVA or FINAL, it is crucial to have the synergistic support from public funding bodies, private entities, and commercial companies. This has been the case in the present study, with different public and private organizations providing economic and logistic support.

The inclusion of brain and blood immune biomarkers will allow us to determine whether LDN modulates neuro-inflammatory processes involving inflammatory cells such as glial cells. These markers will also allow us to explore the “hormetic” effects of the drug, that

1  
2  
3 is, if a low dose of an antagonist (naltrexone) may paradoxically act as an agonist of the  
4  
5 endogenous opiate system. As explained above, it is posited that LDN mainly acts as an  
6  
7 immunomodulatory drug via blockade of TLR-4, which provides a therapeutic pathway to  
8  
9 reduce activation of the inflammatory cascade and the nociceptive system.<sup>71</sup> In a recent pilot  
10  
11 study<sup>72</sup>, patients with opioid induced hyperalgesia and patients with FMS were treated with  
12  
13 LDN for 3 months. Via different mechanisms of action, LDN improved pain tolerance  
14  
15 (measured with the cold pressor test) in both groups of patients, being the effect even stronger  
16  
17 in those participants with opioid induced hyperalgesia. According to the authors, the  
18  
19 neuroimmunological component seems to play an important role in the explanation of the  
20  
21 beneficial effects of LDN in the case of FMS.  
22  
23  
24

25  
26 Obtaining empirical evidence for cost-utility of treatments or interventions is required  
27  
28 by the Ministry of Health in Spain for reimbursement. In Spain, a threshold of €22,000–25,000  
29  
30 per QALY gained is found to be consistent with decisions of adopting new technologies by the  
31  
32 National Health Service.<sup>73</sup> To our knowledge, there is an absence of economic evaluations for  
33  
34 LDN; therefore, an important feature of the present study is the cost-utility assessment of the  
35  
36 drug.  
37  
38  
39

40  
41 FMS remains a chronic, debilitating, and difficult to manage condition for many  
42  
43 individuals around the world. After three decades of intensive research, the clinical benefits of  
44  
45 pharmacological treatments remain unclear and limited. This study will evaluate the analgesic  
46  
47 efficacy, safety, and cost-utility of LDN using a rigorous and powered design. If efficacious  
48  
49 and cost-effective, LDN might be the first drug approved for FMS in Europe.  
50  
51

### 52 **Trial status**

53  
54 This study is currently in the recruitment phase. The first patient will be enrolled in  
55  
56 January 2022, and the study is expected to end in August 2024.  
57  
58

### 59 **Confidentially**

1  
2  
3 Personal data will be stored in accordance with the Spanish regulation guidelines for  
4 clinical research. Participants will be allocated a unique identification (ID) number at entry.  
5  
6 The master list linking participant personal information and ID number will be maintained in  
7  
8 a password-protected hard drive at the PSSJD. Data will be stored for 10 years after study  
9  
10 completion.  
11  
12  
13

### 14 **Contributors**

15  
16 JVL, ARS, and AFS conceived the study and revised the manuscript. JVL drafted the  
17  
18 manuscript. ACC, JPSM, HHN, XB, CSR, AGP, JM, JM, FDA, MM, JWY, AFS and ARS  
19  
20 provided feedback on the manuscript, and all authors reviewed and approved the final version  
21  
22 of the manuscript.  
23  
24  
25

### 26 **Funding**

27  
28 This study has been funded by the Institute of Health Carlos III (ISCIII; ICI20/00080;  
29  
30 CPII19/00003) and has been co-financed with European Union ERDF funds. JPS-M has a PFIS  
31  
32 predoctoral contract from the ISCIII (FI20/00034). AC-C has a FI predoctoral contract from  
33  
34 AGAUR (FI\_B/00216). AF-S acknowledges the funding from the Serra Húnter program  
35  
36 (UAB-LE-8015). The ISCIII did not have any role in the analysis and interpretation of data, in  
37  
38 the writing of the manuscript, or in the decision to submit the paper for publication.  
39  
40  
41  
42

### 43 **Competing interests**

44  
45 None declared.  
46

### 47 **Patient consent for publication**

48  
49 Not required.  
50

### 51 **Provenance and peer review**

52  
53 Not commissioned; externally peer reviewed.  
54  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Häuser W, Ablin J, Fitzcharles MA, *et al.* Fibromyalgia. *Nat Rev Dis Primers* 2015;1:15022.
2. Fietta P, Fietta P, Manganeli P. Fibromyalgia and psychiatric disorders. *Acta Biomed* 2007;78:88-95.
3. Queiroz LP. Worldwide epidemiology of fibromyalgia. *Curr Pain Headache Rep* 2013;17:356.
4. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. *Curr Opin Investig Drugs* 2010;11:16-8.
5. Nüesch E, Häuser W, Bernardy K, *et al.* Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: Network meta-analysis. *Ann Rheum Dis* 2013;72:955-62.
6. Thieme K, Mathys M, Turk DC, *et al.* Evidenced-based guidelines on the treatment of fibromyalgia patients: Are they consistent and if not, why not? Have effective psychological treatments been overlooked? *J Pain* 2017;18:747-56.
7. Cagnie B, Coppieters I, Denecker S, *et al.* Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. *Semin Arthritis Rheum* 2014;44:68-75.
8. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* 2011;152:S2-15.
9. Napadow V, LaCount L, Park K, *et al.* Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. *Arthritis Rheum* 2010;62:2545-55
10. Jensen KB, Berna C, Loggia ML, *et al.* The use of functional neuroimaging to evaluate psychological and other non-pharmacological treatments for clinical pain. *Neurosci Lett* 2012;520:156-64.

- 1  
2  
3 11. Zunhammer M, Schweizer LM, Witte V, *et al.* Combined glutamate and glutamine  
4 levels in pain-processing brain regions are associated with individual pain sensitivity. *Pain*  
5 2016;157:2248-56.  
6  
7
- 8  
9  
10 12. Pyke TL, Osmotherly PG, Baines S. Measuring glutamate levels in the brains of  
11 fibromyalgia patients and a potential role for glutamate in the pathophysiology of  
12 fibromyalgia symptoms. *Clin J Pain* 2017;33:944-54.  
13  
14
- 15  
16  
17 13. Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging  
18 in fibromyalgia taught us about the mechanisms and management of centralized pain?  
19 *Arthritis Res Ther*, 2014;16:425.  
20  
21
- 22  
23  
24 14. Fayed N, Andres E, Rojas G, *et al.* Brain dysfunction in fibromyalgia and somatization  
25 disorder using proton magnetic resonance spectroscopy: a controlled study. *Acta Psychiatr*  
26 *Scand* 2012;126:115-25.  
27  
28
- 29  
30  
31 15. Fayed N, Garcia-Campayo J, Magallón R, *et al.* Localized 1H-NMR spectroscopy in  
32 patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine,  
33 inositol, choline, and N-acetylaspartate. *Arthritis Res Ther* 2010;12:R134.  
34  
35
- 36  
37  
38 16. Harris RE, Sundgren PC, Craig AD, *et al.* Elevated insular glutamate in fibromyalgia  
39 is associated with experimental pain. *Arthritis Rheum* 2009;60:3146-52.  
40  
41
- 42  
43  
44 17. Feraco P, Bacci A, Pedrabissi F, *et al.* Metabolic abnormalities in pain-processing  
45 regions of patients with fibromyalgia: a 3T MR spectroscopy study. *Am J Neurorad*  
46 2011;32:1585-90  
47  
48
- 49  
50  
51 18. Harris RE, Napadow V, Huggins JP, *et al.* Pregabalin rectifies aberrant brain chemistry,  
52 connectivity, and functional response in chronic pain patients. *Anesthesiology*  
53 2013;119:1453-64.  
54  
55
- 56  
57  
58 19. Murga I, Guillen V, Lafuente JV. Cerebral magnetic resonance changes associated with  
59 fibromyalgia syndrome. *Med Clin* 2017;148(11):511-6  
60

- 1  
2  
3 20. Woolf CJ. Pain: moving from symptom control toward mechanism-specific  
4 pharmacologic management. *Ann Intern Med* 2004;140:441-51.  
5  
6
- 7 21. Ji RR, Berta T, Nedergaard M, *et al.* Glia and pain: is chronic pain a gliopathy? *Pain*  
8 2013;154:S10-S28.  
9  
10
- 11 22. Lynch MA. The multifaceted profile of activated microglia. *Mol Neurobiol*  
12 2009;40:139-56.  
13  
14
- 15 23. Watkins LR, Hutchinson MR, Ledebor A, *et al.* Glia as the “bad guys”: implications  
16 for improving clinical pain control and the clinical utility of opioids. *Brain Behav Immun*  
17 2007;21:131-46  
18  
19
- 20 24. Kettenmann H, Hanisch UK, Noda M, *et al.* Physiology of microglia. *Physiol Rev*  
21 2011;91:461-553.  
22  
23
- 24 25. Dantzer R. Cytokine, sickness behavior, and depression. *Immunol Allergy Clin North*  
25 *Am* 2009;29:247-64.  
26  
27
- 28 26. Haroon E, Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio  
29 of trouble in mood disorders. *Neuropsychopharmacol* 2017;42:193-215.  
30  
31
- 32 27. Albrecht DS, Forsberg A, Sandström A, *et al.* Brain glial activation in fibromyalgia -A  
33 multi-site positron emission tomography investigation. *Brain Behav Immun* 2019;75:72-83.  
34  
35
- 36 28. Niraula A, Sheridan JF, Godbout JP. Microglia priming with aging and stress.  
37 *Neuropsychopharmacol.* 2017;42:318.  
38  
39
- 40 29. Andrés-Rodríguez L, Borràs X, Feliu-Soler A, *et al.* Peripheral immune aberrations in  
41 fibromyalgia: A systematic review, meta-analysis and meta-regression. *Brain Behav Immun*  
42 2020;87:881-9.  
43  
44
- 45 30. Bäckryd E, Tanum L, Lind AL, *et al.* Evidence of both systemic inflammation and  
46 neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel  
47 applied to the cerebrospinal fluid and to plasma. *J Pain Res* 2017;10:515.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 31. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation  
4 leading to neuropathic pain. *Curr Opin Pharmacol* 2012;12:55 -61.  
5  
6  
7
- 8 32. Miller AH, Haroon E, Raison CL, *et al.* Cytokine targets in the brain: impact on  
9 neurotransmitters and neurocircuits. *Depress Anxiety* 2013;30:297-306.  
10  
11
- 12 33. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel  
13 anti-inflammatory treatment for chronic pain. *Clin Rheumatol* 2014;33:451-9.  
14  
15
- 16 34. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in  
17 the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia,  
18 Crohn's disease, and other chronic pain disorders. *Pharmacotherapy* 2018;38(3):382-9.  
19  
20  
21  
22
- 23 35. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: A  
24 pilot study. *Pain Med* 2009;10(4):663-72.  
25  
26  
27
- 28 36. Younger J, Noor N, McCue R, *et al.* Low-dose naltrexone for the treatment of  
29 fibromyalgia: findings of a small, randomized, double-blind, placebocontrolled,  
30 counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum.* 2013;65:529-  
31  
32  
33  
34  
35  
36  
37 38.
- 38 37. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-  
39 dose naltrexone for fibromyalgia. *Biomedicines.* 2017;5:16.  
40  
41
- 42 38. Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard  
43 protocol items for clinical trials. *Ann Intern Med* 2013;158:200-7.  
44  
45
- 46 39. Schulz KF, Altman DG, Moher D, *et al.* CONSORT 2010 Statement: updated  
47 guidelines for reporting parallel group randomized trials. *BMJ* 2010;340:c332.  
48  
49
- 50 40. Husereau D, Drummond M, Petrou S, *et al.* Consolidated Health Economic Evaluation  
51 Reporting Standards (CHEERS) statement. *BMC Med* 2013;11:80.  
52  
53  
54
- 55 41. Fayed N, Oliván-Blázquez B, Herrera-Mercadal P, *et al.* Changes in metabolites after  
56 treatment with memantine in fibromyalgia. A double blind randomized controlled trial with  
57  
58  
59  
60



- 1  
2  
3 magnetic resonance spectroscopy with a 6 month follow up. *CNS Neurosci Ther*  
4 2014;20:999-1007.  
5  
6  
7  
8 42. Gálvez-Sánchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia:  
9 Critical Review and Future Perspectives. *J Clin Med* 2020;9(4):1219.  
10  
11  
12 43. Häuser W, Jung E, Erbslöh-Möller B, *et al.* Validation of the fibromyalgia survey  
13 questionnaire within a cross-sectional survey. *PLoS One* 2012;7:e37504.  
14  
15  
16 44. Carrillo-de-la-Peña MT, Triñanes Y, González-Villar A, *et al.* Convergence between  
17 the 1990 and 2010 ACR diagnostic criteria and validation of the Spanish version of the  
18 Fibromyalgia Survey Questionnaire (FSQ). *Rheumatol Int* 2015;35:141–151.  
19  
20  
21  
22 45. Dworkin RH, Turk DC, Wyrwich KW, *et al.* Interpreting the clinical importance of  
23 treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*  
24 2008;9(2):105-21.  
25  
26  
27  
28  
29  
30 46. Bennett RM, Friend R, Jones KD, *et al.* The Revised Fibromyalgia Impact  
31 Questionnaire (FIQR): Validation and psychometric properties. *Arthritis Res Ther*  
32 2009;11:R120.  
33  
34  
35  
36  
37 47. Luciano JV, Aguado J, Serrano-Blanco A, *et al.* Dimensionality, reliability, and validity  
38 of the revised fibromyalgia impact questionnaire in two spanish samples. *Arthritis Care Res*  
39 2013;65:1682–9.  
40  
41  
42  
43  
44 48. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of  
45 the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety  
46 Inventories. *Behav Res Ther* 1995;33:335-43.  
47  
48  
49  
50  
51 49. Alok R., Das SK., Agarwal GG, *et al.* Relationship of severity of depression, anxiety  
52 and stress with severity of fibromyalgia. *Clin Exp Rheumatol* 2011;29(6 Suppl 69):S70-2.  
53  
54  
55  
56 50. Bados A, Solanas A, Andrés R. Psychometric properties of the Spanish version of  
57 Depression, Anxiety and Stress Scales (DASS). *Psicothema* 2005;17:679-83.  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
51. Kratz AL, Schilling SG, Goesling J, *et al.* Development and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia. *J Pain* 2015;16:527–36.
52. Feliu-Soler A, Pérez-Aranda A, Andrés-Rodríguez L, *et al.* Digging into the construct of fibrofog: Psychometric properties of the Spanish version of the Multidimensional Inventory of Subjective Cognitive Impairment in patients with fibromyalgia. *J Appl Biobehav Res* 2018:e12134.
53. Vázquez-Barquero JL, Vázquez Bourgón E, Herrera Castanedo S, *et al.* Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): Initial phase of development and pilot study. Cantabria disability work group. *Actas Esp Psiquiatr* 2000;28:77-87.
54. Smedema SM, Yaghmaian RA, Ruiz D, *et al.* Psychometric validation of the world health organization disability assessment schedule 2.0-12-item version in persons with fibromyalgia syndrome. *J Rehabil* 2016;82(3):28-35
55. Spitzer RL, Kroenke K, Williams JB, *et al.* A brief measure for assessing generalized anxiety disorder: The GAD-7. *Arch Intern Med* 2006;166(10):1092-7
56. Robinson RL, Kroenke K, Williams, DA, *et al.* Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the REFLECTIONS study. *Pain Med.* 2013;14(9):1400-15.
57. Smith SM, Wang AT, Katz NP, *et al.* Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTION systematic review and recommendations. *Pain* 2013;154(7):997-1008.
58. Herdman M, Gudex C, Lloyd A, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
59. Vázquez-Barquero JL, Gaité L, Cuesta MJ, *et al.* Spanish version of the CSRI: a mental health cost evaluation interview. *Arch Neurobiol (Madr)* 1997;60:171-84.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
60. Scott W, McCracken LM. Patients' impression of change following treatment for chronic pain: global, specific, a single dimension, or many? *J Pain* 2015;16:518–26.
61. May M, Junghaenel DU, Ono M, *et al.* Ecological momentary assessment methodology in chronic pain research: A systematic review. *J Pain* 2018;19:699-716.
62. Colombo D., Fernández-Álvarez J, Patané, A, *et al.* Current state and future directions of technology-based ecological momentary assessment and intervention for major depressive disorder: a systematic review. *J Clin Med* 2019;8(4):465.
63. Suso-Ribera C, Castilla D, Zaragoza I, *et al.* Validity, reliability, feasibility, and usefulness of Pain Monitor: A multidimensional smartphone app for daily monitoring of adults with heterogeneous chronic pain. *Clin J Pain* 2018;34:900-8.
64. Ono M, Schneider S, Junghaenel DU, *et al.* What affects the completion of ecological momentary assessments in chronic pain research? An individual patient data meta-analysis. *J Med Internet Res* 2019;21(2):e11398
65. Penedo JMG, Rubel JA, Blättler L, *et al.* The complex interplay of pain, depression, and anxiety symptoms in patients with chronic pain: A network approach. *Clin J Pain* 2020;36:249-59
66. Bringmann LF, Vissers N, Wichers M, *et al.* A network approach to psychopathology: new insights into clinical longitudinal data. *PloS One* 2013;8(4)
67. Love J, Selker R, Marsman M, *et al.* JASP: Graphical statistical software for common statistical designs. *J Stat Softw* 2019;88(2):1-17.
68. Bruun-Plesner KD, Blichfeldt-Eckhardt MR, Vaegter HB, *et al.* Low-dose naltrexone for the treatment of fibromyalgia: Investigation of dose–response relationships. *Pain Med* 2020;21(10):2253-61.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
69. Bruun-Plesner KD, Amris K, Vaegter, HB, *et al.* Low dose naltrexone for the treatment of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial, 08 April 2021, PREPRINT (Version 1) available at *Research Square*.
70. Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. *Curr Pain Headache Rep* 2020;24(10):1-8
71. Hatfield E, Phillips K, Swidan S, *et al.* Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review. *J Am Dent Assoc* 2020;151(12):891-902.
72. Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. *Front Psychiatry*. 2021; 12: 593842.
73. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. *Health Econ* 2018;27(4):746-61.

**Table 1.** Time points for data collection.

Measures	T0 (baseline)	T1 (3-m)	T2 (6-m)	T3 (12-m)
<i>Sociodemographic, clinical, and screening measures</i>				
Sociodemographic data	X			
Clinical data (years of evolution, comorbidities, etc.)	X			
FSDC screening and secondary outcome measure (fibromyalginess)	X	X	X	X
<i>Primary outcome measure</i>				
NRS (pain intensity)	X	X	X	X
<i>Secondary outcome measures</i>				
FIQR (functional impairment)	X	X	X	X
DASS-21 (anxiety, depression, and stress)	X	X	X	X
MISCI (subjective cognitive impairment)	X	X	X	X
WHODAS 2.0 (disability)	X	X	X	X
GAD-7 (general anxiety / worry)	X	X	X	X
<i>Other measures</i>				
EQ-5D-5L (quality of life)	X			X
CSRI (medication consumption and service receipt)	X			X
PGIC and PSIC (impression of change)		X	X	X
ACTTION checklist (adverse events throughout the trial)	X	X	X	X
Pain Monitor® app (EMA)	X	X		
<b>Physiological variables</b>				
Immune biomarkers	X	X		
Neuroimaging	X	X		

ACTTION checklist: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; CSRI: Client Service Receipt Inventory; DASS-21: Depression Anxiety Stress Scales-21; EQ-5D-5L: EuroQoL; EMA: Ecological Momentary Assessment; FIQR: Fibromyalgia Impact Questionnaire Revised; FSDC: Fibromyalgia Survey Diagnostic Criteria; GAD-7: Generalized Anxiety Disorder 7-item scale; NRS: Numerical Pain Rating Scale; PGIC and PSIC= Patient Global Impression of Change and Pain Specific Impression of Change; WHODAS 2.0: 12-item interviewer administered version of the World Health Organization Disability Assessment Schedule 2.0

**Table 2.** List of items administered via Pain Monitor® app.

Items	Morning	Evening
Pain intensity	X	X
Fatigue	X	X
Perceived control over pain	X	X
Depression	X	X
Anxiety	X	X
Stress	X	X
Sleep disturbance	X	
Activity level		X
Interference with leisure activities		X
Interference with work-related activities		X
Adverse effects		X
Rescue medications		X

The Pain Monitor app automatically informs patients when to respond (by default, at 11 AM and 7 PM) using a push notification system, but patients can respond with a margin of 2 hours from given times. Collected data are stored on a secure server at the Jaume I University, Spain.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Flowchart of the INNOVA study based on the CONSORT guidelines.

For peer review only




Figure 1. Flowchart of the INNOVA study based on the CONSORT guidelines.

190x275mm (96 x 96 DPI)





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item N°	Description	Pages
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration	2b	All items from the World Health Organization Trial Registration Data Set	n.a
	3	Date and version identifier	n.a
Protocol version	3	Date and version identifier	n.a
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,23
	5b	Name and contact information for the trial sponsor	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-8
	6b	Explanation for choice of comparators	8
Objectives	7	Specific objectives or hypotheses	8

1			
2		Description of trial design including type of trial (eg, parallel	
3		group, crossover, factorial, single group), allocation ratio, and	
4	Trial design	8 framework (eg, superiority, equivalence, noninferiority,	8
5		exploratory)	
6			
7			
8		<b>Methods: Participants, interventions, and outcomes</b>	
9			
10		Description of study settings (eg, community clinic, academic	
11	Study setting	9 hospital) and list of countries where data will be collected.	10
12		Reference to where list of study sites can be obtained	
13			
14		Inclusion and exclusion criteria for participants. If applicable,	
15	Eligibility criteria	10 eligibility criteria for study centres and individuals who will	9
16		perform the interventions (eg, surgeons, psychotherapists)	
17			
18			
19		11a Interventions for each group with sufficient detail to allow	11
20		replication, including how and when they will be administered	
21			
22		Criteria for discontinuing or modifying allocated interventions for	
23		11b a given trial participant (eg, drug dose change in response to	12
24		harms, participant request, or improving/worsening disease)	
25	Interventions		
26		Strategies to improve adherence to intervention protocols, and	
27		11c any procedures for monitoring adherence (eg, drug tablet return,	10
28		laboratory tests)	
29			
30		11d Relevant concomitant care and interventions that are permitted	11
31		or prohibited during the trial	
32			
33			
34		Primary, secondary, and other outcomes, including the specific	
35		measurement variable (eg, systolic blood pressure), analysis	12-18
36		metric (eg, change from baseline, final value, time to event),	Table 1
37	Outcomes	12 method of aggregation (eg, median, proportion), and time point	Table 2
38		for each outcome. Explanation of the clinical relevance of	
39		chosen efficacy and harm outcomes is strongly recommended	
40			
41			
42		Time schedule of enrolment, interventions (including any run-ins	
43	Participant	13 and washouts), assessments, and visits for participants. A	Fig. 1
44	timeline	schematic diagram is highly recommended (see Figure)	
45			
46		Estimated number of participants needed to achieve study	
47		objectives and how it was determined, including clinical and	9
48	Sample size	14 statistical assumptions supporting any sample size calculations	
49			
50			
51		Strategies for achieving adequate participant enrolment to reach	
52	Recruitment	15 target sample size	10
53			

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2			Method of generating the allocation sequence (eg, computer-	
3			generated random numbers), and list of any factors for	
4	Sequence		stratification. To reduce predictability of a random sequence,	
5	generation	16a	details of any planned restriction (eg, blocking) should be	10
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocation		Mechanism of implementing the allocation sequence (eg, central	
11	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
12	mechanism	16b	describing any steps to conceal the sequence until interventions	10
13			are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence, who will enrol	10
16			participants, and who will assign participants to interventions	
17				
18				
19			Who will be blinded after assignment to interventions (eg, trial	
20		17a	participants, care providers, outcome assessors, data analysts),	10-11
21			and how	
22	Blinding (masking)			
23			If blinded, circumstances under which unblinding is permissible,	
24		17b	and procedure for revealing a participant's allocated intervention	11
25			during the trial	
26				
27				
28	<b>Methods: Data collection, management, and analysis</b>			
29				
30			Plans for assessment and collection of outcome, baseline, and	
31			other trial data, including any related processes to promote data	
32			quality (eg, duplicate measurements, training of assessors) and	
33		18a	a description of study instruments (eg, questionnaires,	12-18
34			laboratory tests) along with their reliability and validity, if known.	
35	Data collection		Reference to where data collection forms can be found, if not in	
36	methods		the protocol	
37				
38				
39			Plans to promote participant retention and complete follow-up,	
40		18b	including list of any outcome data to be collected for participants	10
41			who discontinue or deviate from intervention protocols	
42				
43				
44			Plans for data entry, coding, security, and storage, including any	
45			related processes to promote data quality (eg, double data entry;	
46	Data management	19	range checks for data values). Reference to where details of	11
47			data management procedures can be found, if not in the	
48			protocol	
49				
50				
51			Statistical methods for analysing primary and secondary	
52		20a	outcomes. Reference to where other details of the statistical	18-19
53	Statistical		analysis plan can be found, if not in the protocol	
54	methods			
55				
56		20b	Methods for any additional analyses (eg, subgroup and adjusted	19-20
57			analyses)	
58				
59				
60				

1			
2		Definition of analysis population relating to protocol non-	
3	20c	adherence (eg, as randomised analysis), and any statistical	18
4		methods to handle missing data (eg, multiple imputation)	
5			
6			
7		<b>Methods: Monitoring</b>	
8			
9		Composition of data monitoring committee (DMC); summary of	
10		its role and reporting structure; statement of whether it is	
11	21a	independent from the sponsor and competing interests; and	
12		reference to where further details about its charter can be found,	
13	Data monitoring	if not in the protocol. Alternatively, an explanation of why a DMC	
14		is not needed	
15			
16		Description of any interim analyses and stopping guidelines,	
17	21b	including who will have access to these interim results and make	18
18		the final decision to terminate the trial	
19			
20			
21		Plans for collecting, assessing, reporting, and managing	
22	Harms	solicited and spontaneously reported adverse events and other	14
23		unintended effects of trial interventions or trial conduct	
24			
25		Frequency and procedures for auditing trial conduct, if any, and	
26	Auditing	whether the process will be independent from investigators and	11
27		the sponsor	
28			
29			
30		<b>Ethics and dissemination</b>	
31			
32	Research ethics	Plans for seeking research ethics committee/institutional review	
33	approval	board (REC/IRB) approval	21
34			
35		Plans for communicating important protocol modifications (eg,	
36	Protocol	changes to eligibility criteria, outcomes, analyses) to relevant	
37	amendments	parties (eg, investigators, REC/IRBs, trial participants, trial	21
38		registries, journals, regulators)	
39			
40			
41		Who will obtain informed consent or assent from potential trial	
42	26a	participants or authorised surrogates, and how (see Item 32)	10
43	Consent or assent		
44		Additional consent provisions for collection and use of	
45	26b	participant data and biological specimens in ancillary studies, if	n.a
46		applicable	
47			
48		How personal information about potential and enrolled	
49	Confidentiality	participants will be collected, shared, and maintained in order to	23
50		protect confidentiality before, during, and after the trial	
51			
52			
53	Declaration of	Financial and other competing interests for principal	
54	interests	investigators for the overall trial and each study site	24
55			
56		Statement of who will have access to the final trial dataset, and	
57	Access to data	disclosure of contractual agreements that limit such access for	21
58		investigators	
59			
60			

1				
2	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for	n.a
3	trial care		compensation to those who suffer harm from trial participation	
4				
5			Plans for investigators and sponsor to communicate trial results	
6			to participants, healthcare professionals, the public, and other	
7		31a	relevant groups (eg, via publication, reporting in results	21
8			databases, or other data sharing arrangements), including any	
9			publication restrictions	
10	Dissemination			
11	policy			
12		31b	Authorship eligibility guidelines and any intended use of	24
13			professional writers	
14				
15		31c	Plans, if any, for granting public access to the full protocol,	8
16			participant-level dataset, and statistical code	
17				
18				
19	<b>Appendices</b>			
20	Informed consent	32	Model consent form and other related documentation given to	Attached
21	materials		participants and authorised surrogates	
22				
23			Plans for collection, laboratory evaluation, and storage of	
24	Biological	33	biological specimens for genetic or molecular analysis in the	17
25	specimens		current trial and for future use in ancillary studies, if applicable	
26				
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055351.R2
Article Type:	Protocol
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	Colomer-Carbonell, Ariadna; Institut de Recerca Sant Joan de Déu, Teaching, Research & Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology Sanabria-Mazo, Juan; Institut de Recerca Sant Joan de Déu, Teaching, Research & Innovation Unit - Parc Sanitari Sant Joan de Déu; Autonomous University of Barcelona, Department of Basics, Developmental and Educational Psychology Hernández-Negrín, Halbert; Universidad de Ciencias Médicas de Villa Clara Borràs, Xavier; Autonomous University of Barcelona, Susó-Ribera, Carlos; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology García-Palacios, Azucena; Universitat Jaume I, Department of Basic and Clinical Psychology and Psychobiology Muchart, Jordi; Hospital Sant Joan de Déu, Diagnostic Imaging Department Munuera, Josep; Hospital Sant Joan de Déu, Diagnostic Imaging Department D'Amico, Francesco; London School of Economics and Political Science, Personal Social Services Research Unit Maes, Michael; Chulalongkorn University, Department of Psychiatry Younger, Jarred; University of Alabama at Birmingham Feliu-Soler, Albert; Autonomous University of Barcelona, Department of Clinical and Health Psychology Rozadilla-Sacanell, Antoni; Institut de Recerca Sant Joan de Déu, Department of Rheumatology - Parc Sanitari Sant Joan de Déu Luciano, Juan; Parc Sanitari Sant Joan de Déu, Teaching, Research & Innovation Unit; Universitat Autònoma de Barcelona, Clinical and Health Psychology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Health economics, Pharmacology and therapeutics, Public health
Keywords:	PAIN MANAGEMENT, HEALTH ECONOMICS, Clinical trials <

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	THERAPEUTICS

SCHOLARONE™  
Manuscripts

1  
2  
3 **Study protocol for a randomised, double-blinded, placebo-controlled phase III trial**  
4  
5 **examining the add-on efficacy, cost-utility and neurobiological effects of low-dose**  
6  
7 **naltrexone (LDN) in patients with fibromyalgia (INNOVA study)**  
8  
9

10  
11  
12 Ariadna Colomer-Carbonell<sup>1,2,3\*</sup>. ORCID: 0000-0001-8923-6316

13  
14  
15 Juan P. Sanabria-Mazo<sup>1,2,3\*</sup>. ORCID: 0000-0003-1688-435X

16  
17  
18 Halbert Hernández-Negrín<sup>4\*</sup>. ORCID: 0000-0002-9992-9148

19  
20  
21 Xavier Borràs<sup>3</sup>. ORCID: 0000-0003-3972-1385

22  
23  
24 Carlos Suso-Ribera<sup>5,6</sup>. ORCID: 0000-0002-2655-1017

25  
26  
27 Azucena García-Palacios<sup>5,6</sup>. ORCID: 0000-0001-9250-8714

28  
29  
30 Jordi Muchart<sup>7</sup>. ORCID: 0000-0003-4702-5072

31  
32  
33 Josep Munuera<sup>7</sup>. ORCID: 0000-0001-5154-1796

34  
35  
36 Francesco D'Amico<sup>8</sup>. ORCID: 0000-0001-5289-9300

37  
38  
39 Michael Maes<sup>9</sup>. ORCID: 0000-0002-2012-871X

40  
41  
42 Jarred W. Younger<sup>10</sup>. ORCID: 0000-0003-3616-9919

43  
44  
45 Albert Feliu-Soler<sup>11\*\*</sup>. ORCID: 0000-0003-2810-7670

46  
47  
48 Antoni Rozadilla-Sacanel<sup>1,12,13\*\*</sup>. ORCID: 0000-0002-7555-189X

49  
50  
51 Juan V. Luciano<sup>1,2,11\*\*</sup>. ORCID: 0000-0003-0750-1599

52  
53  
54 **Author affiliations**

55  
56  
57 <sup>1</sup>Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain

58  
59  
60 <sup>2</sup>Teaching, Research & Innovation Unit, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat, Spain

<sup>3</sup>Department of Basics, Developmental and Educational Psychology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain



1  
2  
3 <sup>4</sup>Hospital Universitario Arnaldo Milián Castro & Universidad de Ciencias Médicas de Villa  
4 Clara, Santa Clara, Cuba.

5  
6  
7  
8 <sup>5</sup>Department of Basic and Clinical Psychology and Psychobiology, University Jaume I,  
9 Castellon de la Plana, Spain

10  
11  
12 <sup>6</sup>Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERObn),  
13 Institute of Health Carlos III, Madrid, Spain

14  
15  
16  
17 <sup>7</sup>Diagnostic Imaging Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain

18  
19  
20 <sup>8</sup>Personal Social Services Research Unit, London School of Economics and Political Science,  
21 London, UK

22  
23  
24 <sup>9</sup>Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand

25  
26  
27 <sup>10</sup>Department of Psychology, University of Alabama at Birmingham, Birmingham, USA

28  
29  
30 <sup>11</sup>Department of Clinical and Health Psychology, Autonomous University of Barcelona,  
31 Cerdanyola del Vallès, Spain

32  
33  
34 <sup>12</sup> Rheumatology Service, Parc Sanitari Sant Joan de Déu, St. Boi de Llobregat, Spain

35  
36  
37 <sup>13</sup>School of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain

38  
39  
40  
41 \*AC-C, JPS-M and HH-N are joint first authors.

42  
43  
44 \*\*AF-S, AR-S and JVL are joint senior authors.

45  
46  
47  
48  
49  
50  
51  
52 **Correspondence**

53  
54 Juan V. Luciano. Department of Clinical & Health Psychology, Autonomous University of  
55 Barcelona. 08193, Cerdanyola del Vallès, Spain. E-mail: [juanvicente.luciano@uab.cat](mailto:juanvicente.luciano@uab.cat)

## ABSTRACT

**Introduction.** There is evidence that low-dose naltrexone (LDN; < 5.0 mg/day) reduces pain and improves the quality of life of people with fibromyalgia syndrome (FMS). However, no randomised controlled trials with long-term follow-ups have been carried out. The INNOVA study will evaluate the add-on efficacy, safety, cost-utility, and neurobiological effects of LDN for reducing pain in FMS patients, with a one-year follow-up.

**Methods and analysis.** A single-site, prospective, randomised, double-blinded, placebo-controlled, parallel design phase III trial will be performed. Eligibility criteria include being adult, having a diagnosis of FMS and experiencing pain of 4 or higher on a 10-point numerical rating scale. Participants will be randomised to a LDN intervention group (4.5 mg/day) or to a placebo control group. Clinical assessments will be performed at baseline (T0), 3-months (T1), 6-months (T2), and 12-months (T3). The primary endpoint will be pain intensity. A sample size of 60 patients per study arm (120 in total), as calculated prior to recruitment for sufficient power, will be monitored between January 2022 and August 2024. Assessment will also include daily ecological momentary evaluations of FMS-related symptoms (e.g., pain intensity, fatigue, and sleep disturbance), and side effects via ecological momentary assessment (EMA) through the Pain Monitor app® during the first three months. Costs and quality-adjusted life years will be also calculated. Half of the participants in each arm will be scanned with magnetic resonance imaging (MRI) at T0 and T1 for changes in brain metabolites related to neuroinflammation and central sensitization. Inflammatory biomarkers in serum will also be measured.

**Ethics and dissemination.** This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media, and community engagement activities.

**Trial registration number:** ClinicalTrials.gov (NCT04739995)

### Strengths and limitations of this study

- This is thought to be the first randomised, double-blinded, placebo-controlled phase III trial to assess the efficacy, safety, cost-utility, and neurobiological effects of low-dose naltrexone (LDN) for reducing pain in patients with fibromyalgia syndrome.
- The INNOVA protocol combines mobile-technology-based ecological momentary assessment and assessment with classical legacy measures to obtain more precise information on the dynamics of the assessed primary and secondary outcomes.
- This study will include immune and neuroimaging biomarkers in order to explore the neurobiological underpinnings of LDN.
- Challenges of the RCT include the long follow-up period (one year) and potential measurement burden that takes the risk of high dropout rate.

## INTRODUCTION

### **Fibromyalgia: definition, prevalence, and pharmaceutical indications**

Fibromyalgia syndrome (FMS) is a chronic condition of unknown origin that is characterised by generalised musculoskeletal pain, fatigue, stiffness, cognitive problems, sleep disturbances, and malaise.<sup>1,2</sup> This syndrome is highly prevalent in the general population (2.7% worldwide).<sup>3</sup> Around 6% of adult patients who visit their general practitioner, and between 10-20% of those who visit rheumatology services, have FMS.<sup>2</sup> In 2007, the U.S. Food and Drug Administration approved pregabalin as the first drug indicated for the treatment of FMS, and later approved duloxetine and milnacipran for this indication. However, the European regulatory authorities rejected the indication of these three drugs in the treatment of FMS given the small effect sizes in various studies and the associated adverse effects.<sup>4-6</sup>

### **Pathogenesis of FMS**

Although the etiological factors of FMS are not known, the primary hypothesis of the pathogenesis of this syndrome highlights the role of the central nervous system in the amplification of pain perception as well as in the development of comorbid symptoms such as sleep-related problems, fatigue, cognitive difficulties, and emotional distress.<sup>1,7,8</sup> Structural brain alterations have also been found in patients with FMS. For example, lower volumes of grey matter have been observed in areas associated with the processing of stress (e.g., parahippocampal gyrus) and pain (e.g., anterior cingulate cortex, insula, prefrontal cortex, and primary and secondary somatosensory cortices).<sup>7</sup> Functional MRI alterations been associated with self-reported pain intensity. Brain activity exhibited greater connectivity between different pain-processing areas (e.g., insula and secondary somatosensory cortex), the default-model network in persons with FMS, as well as in the association between these areas and the pain levels reported by patients and the right executive attention network.<sup>9</sup>

1  
2  
3 Altered functional connectivity has also been reported among various pain-inhibiting  
4 areas.<sup>10</sup> Some studies have reported reduced levels of neurotransmitters involved in the  
5 regulation of the descending analgesic response (serotonin and noradrenaline) and increased  
6 levels of glutamate (Glu) and substance P in people with FMS.<sup>11-14</sup> For example, high levels of  
7 Glu have been reported in the posterior insula, posterior cingulate cortex and prefrontal  
8 ventrolateral cortex of patients with FMS when compared to healthy controls<sup>15-19</sup>.

17  
18 Activation of the microglia could be a contributing factor to the alteration of glutamate  
19 neurotransmission in FMS.<sup>20,21</sup> The microglia is normally found in a state of rest but it is  
20 activated by a wide range of stimuli such as cell death, peripheral inflammation, chronic stress  
21 and infections.<sup>22</sup> Once activated, microglia release pro-inflammatory agents such as cytokines,  
22 excitatory amino acids and nitric oxide.<sup>23</sup> These inflammatory factors across multiple neural  
23 pathways can induce hyperalgesia, fatigue, depression and other symptoms which are known  
24 collectively as “cytokine induced sickness behavior”.<sup>24,25</sup> Microglia activation might trigger a  
25 series of actions that lead to an increase in Glu that ultimately results in synaptic dysfunction.<sup>26</sup>  
26 A recent study using Positron Emission Tomography<sup>27</sup> of translocator protein revealed a  
27 widespread cortical glial activation in patients with FMS, which gives support to the role of  
28 neuroinflammation in the aetiology of FMS. In addition, there is evidence that chronic stress  
29 facilitates the “priming” and exaggerated activation of the microglia.<sup>28</sup>

35  
36 Although FMS is not considered a classic inflammatory disease, there is extensive  
37 evidence that immune pathways play a significant role in the pathogenesis and maintenance of  
38 the syndrome. Cytokines play a key role in inflammatory response and in boosting the  
39 nociceptive response due to their sensitization actions, both on a peripheral and central level.<sup>29-</sup>  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Although FMS is not considered a classic inflammatory disease, there is extensive evidence that immune pathways play a significant role in the pathogenesis and maintenance of the syndrome. Cytokines play a key role in inflammatory response and in boosting the nociceptive response due to their sensitization actions, both on a peripheral and central level.<sup>29-</sup>  
<sup>32</sup> Thus, there is evidence that FMS involves an imbalance in pro-inflammatory (e.g. IL-1, IL-6, IL-17A, and TNF- $\alpha$ ) and anti-inflammatory (e.g. IL-4 and IL-10) levels of cytokines that could lead to a low-intensity, chronic state of inflammation. Bäckryd and colleagues<sup>30</sup>

1  
2  
3 identified both neuroinflammation and systemic inflammation by evaluating levels of a broad  
4 panel of cytokines and chemokines in cerebrospinal fluid and plasma.  
5  
6  
7

### 8 **Low-dose naltrexone (LDN): A promising treatment for FMS**

9

10  
11 Naltrexone is an opioid antagonist medication used to treat opioid and alcohol  
12 dependency. The drug blocks mu-opioid receptors, the delta-opioid receptors and, to a lesser  
13 extent, the kappa-opioid receptors. There is promising evidence to suggest that naltrexone  
14 administered in low doses (i.e., low-dose naltrexone; < 5 mg/day) is effective in the  
15 management of some pathologies which present with altered immune pathways, such as  
16 Crohn's disease, multiple sclerosis, or FMS.<sup>33,34</sup> The immune-regulatory effect of LDN seems  
17 to be driven through the inhibition of the Toll-like receptor 4 (TLR-4) activity expressed in the  
18 membrane of various immune system cells (e.g., microglia and macrophages).<sup>33</sup> Moreover, due  
19 to a “rebound effect”, LDN could exert an analgesic effect that strengthens the endogenous  
20 opioid pain inhibitory system. According to this hypothesis, the low-intensity and intermittent  
21 blockade of the opioid receptors generated by LDN induces a compensatory mechanism that  
22 facilitates an increase in the production of endogenous opioids and greater sensitivity of the  
23 system to their effects.<sup>33,34</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 To date, the effects of LDN in patients with FMS have only been evaluated through  
42 crossover pilot studies that have yielded preliminary results. In the first study conducted with  
43 LDN in FMS, significant reductions in pain, stress, and fatigue levels were observed.<sup>35</sup> In a  
44 subsequent study, significant improvements in daily pain, satisfaction with life and mood were  
45 also observed.<sup>36</sup> In another crossover investigation, the pre and post changes in the levels of  
46 plasma cytokines were evaluated over eight weeks. Significant reductions in a wide range of  
47 immune biomarkers were obtained (e.g., IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, IL-10, IL-17A, and TNF-  
48  $\alpha$ ), together with a reduction in the pain levels and the severity of FMS symptoms.<sup>37</sup>  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 While acknowledging the contribution of past studies into the field, these have included  
4 small sample sizes (n= 8 to 31 participants) and crossover designs. Therefore, a single-site,  
5 prospective, randomised, double-blinded, placebo-controlled study (RCT) with a sufficiently  
6 powered sample is presented here to conduct a methodologically robust investigation into the  
7 role of LDN in FMS. Specifically, the main objective of the INNOVA study is to evaluate the  
8 efficacy, safety, and cost-utility, and neurobiological effects of LDN to reduce pain in FMS.  
9  
10 There is currently no gold standard pharmacological treatment for pain reduction in persons  
11 with FMS. Therefore, in the present study, placebo will be used instead of another drug in the  
12 control group.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **METHODS AND ANALYSIS**

### 25 **Trial design**

26  
27 The randomised controlled trial (RCT) protocol has been developed following the  
28 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)<sup>38</sup>. In addition,  
29 the RCT was approved by European Union Drug Regulating Authorities Clinical Trials  
30 (EudraCT; 2021-002534-16). For reporting purposes, we will follow the guidelines of the  
31 Consolidated Standards of Reporting Trials (CONSORT)<sup>39</sup> and the Consolidated Health  
32 Economic Evaluation Reporting Standards (CHEERS) statement.<sup>40</sup> INNOVA is a 12-month  
33 double-blind RCT with two arms: LDN vs. Placebo. LDN will be considered an add-on  
34 treatment to the usual care provided in the Spanish National Health System for FMS. For  
35 transparency and analytical reproducibility purposes, the dataset and data coding will be  
36 deposited in the Open Science Framework.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Sample size**

53  
54 There are no previous RCTs about the efficacy of LDN for FMS, therefore, we  
55 estimated the sample size taking into account a previous LDN crossover study<sup>36</sup> that had used  
56 self-reported pain as main outcome (the effect size was  $d = .99$ ). Thus, with a sample of 60  
57  
58  
59  
60

1  
2  
3 participants per arm, we aim to detect between-group differences with a significance level of  
4  
5 5% and a power of 80%. Allowing for a potential attrition rate of 20%, our final sample size is  
6  
7 60 participants per group. For the analysis of biomarkers (involving 50% of the sample), an  
8  
9 initial sample size of 30 patients per arm is considered sufficient according to previous  
10  
11 studies.<sup>37,41</sup>

## 12 13 14 15 **Eligibility criteria**

16  
17 *General selection criteria.* All participants will meet the following inclusion criteria:  
18  
19 women between 18-70 years; diagnoses of FMS according to American College of  
20  
21 Rheumatology 2016 criteria<sup>42</sup> by a rheumatologist; pain intensity ranked  $\geq 4$  out of 10 on a 10-  
22  
23 point numerical rating scale in the past week; fluent in Spanish; provision of written informed  
24  
25 consent; stable pharmacological treatment in the last two months; and having a smartphone  
26  
27 with android operating system for Ecological Momentary Assessment (EMA). Potential  
28  
29 participants will be excluded according to the following exclusion criteria: treatment with  
30  
31 naltrexone, opioids, anticoagulants, or central anti-hypertensives in the last 3 months; diagnosis  
32  
33 of severe medical/psychiatric disorders (e.g., cancer, haematological diseases, abnormal  
34  
35 hepatic/liver function, renal failure, suicide ideation, psychotic disorder); pregnant (or planning  
36  
37 to become pregnant during the study period) or breastfeeding; known allergy to naltrexone,  
38  
39 naloxone or excipients; currently participating in other RCTs; ongoing litigation related to  
40  
41 FMS.  
42  
43  
44  
45  
46

47  
48 *Additional selection criteria for the biomarkers and neuroimaging sub-study (50% of*  
49  
50 *patients in each study arm).* All participants will meet the following inclusion criteria:  
51  
52 right-handed (for the neuroimaging tests); and no comorbid rheumatologic conditions (e.g.,  
53  
54 rheumatoid arthritis, lupus). Potential participants will be excluded according to the following  
55  
56 exclusion criteria: fever ( $> 38^{\circ}\text{C}$ ); infection in the last two weeks; vaccination in the last month;  
57  
58 taking cortisone or anti-cytokine therapy; needle phobia or claustrophobia, metal implants or  
59  
60



1  
2  
3 pacemakers; body mass index  $\geq 36$  kg/m<sup>2</sup>; smoking over 5 cigarettes/day; presence of acute  
4  
5 pain (e.g, headache or back pain) unrelated to FMS on the day of the scan.  
6  
7

### 8 **Recruitment strategy, procedure and randomisation**

9

10 Patients diagnosed with FMS with an appointment at the Rheumatology Service of Parc  
11 Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) will be invited to participate in the  
12 study and will be asked to attend a screening evaluation with a research assistant and a clinician.  
13  
14 Once the informed consent is obtained, the clinician will review the study selection criteria to  
15 confirm eligibility. The week after, a face-to-face assessment (T0) including clinical history  
16 and variables related to the use of services will be conducted with those patients meeting all  
17 the eligibility criteria. Only the participants that are included in the biomarkers sub-study will  
18 require an additional blood extraction and neuroimaging scan, which will be performed in the  
19 following 3-5 days. Participants will be given a sealed envelope with an identifying code which  
20 they will have to take to the pharmacy service. There, they will be given the dose of the  
21 corresponding drug (according to the randomisation) for the first 3 months (90 tablets). As  
22 shown in the patients' flow chart (Figure 1), further in-person evaluations will be performed at  
23 3 months (T1), 6 months (T2), and 12 months (T3). Neurobiological variables will be obtained  
24 at T1 using the same protocol as in the baseline assessment (T0).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Participants will be asked to abstain from taking any analgesic or anti-inflammatory  
43 drug in the 72h prior to the blood extractions/scans. All patients, including those who do not  
44 participate in the biomarker sub-study, shall be subjected to a blood test at baseline. Participants  
45 will return to the pharmacy service every 3 months and will be given the assigned amount of  
46 LDN/placebo for the following 3 months (approximately 90 tablets). Unconsumed tablets will  
47 be returned for treatment adherence monitoring. The randomisation to conditions will be  
48 conducted by a biostatistician from the Clinical Trials Unit of Fundació Sant Joan de Déu who  
49 has no involvement in the eligibility screening, enrolment, and treatment processes. The  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 computer-generated randomisation will apply a permuted block design to ensure that the study  
4 arms are balanced taking the biomarkers sub-study eligibility criteria into account. As this is a  
5 double-blind RCT, neither the patient nor the evaluator or the clinician will know to which  
6 treatment arm each patient has been assigned. Only the clinical trial pharmacist who stores and  
7 delivers capsules, but is not involved in patient care, will know the allocation.  
8  
9  
10  
11  
12  
13

14  
15 Figure 1

### 16 17 **Data management, central monitoring and audit**

18  
19 The clinical data entry, data management, and central monitoring will be performed  
20 with REDCap®. An independent Clinical Research Organization (CRO) will be responsible  
21 for overseeing the intra-study data sharing and storing process. Any modifications in the study  
22 protocol will be communicated to the CRO.  
23  
24  
25  
26  
27

### 28 29 **Treatments**

30  
31 **Low-dose naltrexone (LDN).** The intervention group will take one 4.5 mg naltrexone  
32 tablet (lactose-free) daily for 12 months before going to sleep.  
33  
34

35  
36 **Placebo.** The control group will take the placebo daily for 12 months (a film-coated  
37 tablet identical to the LDN and filled with a lactose-free filler). For the control arm, the same  
38 guidelines will be followed.  
39  
40  
41

42  
43 In order to maintain the external validity of the study and for ethical reasons, the study  
44 participants' active treatments will be unchanged by this clinical trial. In Spain, chronic pain  
45 management is mainly managed by general practitioners in regular consultations. These  
46 generally consist of face-to-face appointments with a duration of 5-10 minutes in which the  
47 clinicians monitor the physical and, ideally, the emotional status of the patient. General  
48 practitioners usually provide advice prescribe pharmacotherapy (pain killers, hypnotics,  
49 antidepressants, etc.) or refer patients to pain units in tertiary hospitals when more specialised  
50 pain management procedures are required. The frequency of consultations is based on the type  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of disease and its severity. In this study, usual care will be the same as in routine daily practice,  
4  
5 without any modifications. In addition, participants will be allowed to withdraw from this study  
6  
7 for any reason at any time without detriment to the provision or quality of their usual care. If a  
8  
9 severe adverse event occurs, unblinding will be possible and study participation will be  
10  
11 discontinued. If the adverse effects are tolerable, the treatment will be administered until the  
12  
13 end of the study. All these events will be recorded and reported at the end of the study.  
14  
15

### 16 17 **Study measures**

18  
19 All participants will be assessed with a computer-administered battery of measures  
20  
21 using the REDCap® software (see Table 1).  
22  
23

24  
25 Table 1

### 26 27 **Measures for sociodemographic characteristics, clinical features, and screening**

28  
29 A *sociodemographic questionnaire* will be used to obtain information about the  
30  
31 following variables: gender, date of birth, marital status, living arrangements, educational level,  
32  
33 income level, and employment status.  
34  
35

36  
37 The *Clinical data* interview will be used to collect information about history and  
38  
39 duration of FMS symptoms, as well as family history of medical/mental illness. Information  
40  
41 regarding comorbidity with other diagnosed physical-psychiatric conditions and the type and  
42  
43 dose of current drugs will be checked from medical records.  
44

45  
46 The *Fibromyalgia Survey Diagnostic Criteria* (FSDC)<sup>43,44</sup> is a 6-item self-report  
47  
48 measure of the core FMS symptoms according to the latest revision of the American College  
49  
50 of Rheumatology (ACR) 2016 criteria.<sup>42</sup> It includes two subscales: the Widespread Pain Index,  
51  
52 which is used to identify the presence of pain in 19 body areas in the last week, and the  
53  
54 Symptom Severity Scale, in which the three major FMS symptoms (fatigue, “fibrofog” and  
55  
56 waking up tired) are assessed along with three additional symptoms (pain in the lower stomach,  
57  
58  
59  
60

1  
2  
3 depression and headache). A total score is obtained by adding the two subscales. This total  
4  
5 score ranges from 0 to 31, where higher values indicate greater FMS severity.  
6  
7

### 8 **Primary outcome measure**

9

10 The *Numeric Rating Scale* (NRS)<sup>45</sup> is a unidimensional measure of pain intensity  
11  
12 mainly used for adults. The most frequently used version is an 11-point numeric scale (a  
13  
14 horizontal bar or line) scored from 0 (“no pain”) to 10 (“worst pain imaginable”). Time frames  
15  
16 vary between studies. In the present study, respondents will be asked to report average pain  
17  
18 intensity over the last week.  
19  
20  
21

### 22 **Secondary outcome measures**

23

24 The *Revised Fibromyalgia Impact Questionnaire* (FIQR)<sup>46</sup> includes 21 items that are  
25  
26 answered on a 0 to 10 numerical scale in which higher scores indicate greater functional  
27  
28 impairment. The questionnaire asks about the previous seven days. The items are distributed  
29  
30 into three domains: physical impairment, overall impact, and severity of symptoms (i.e., pain,  
31  
32 energy, stiffness, sleep quality, depression, memory issues, anxiety, pain to the touch, balance  
33  
34 problems and increased sensitivity to noises, lights, smells, or temperatures). A total score is  
35  
36 obtained by summing the three subscale scores. This can range from 0 to 100. Higher scores  
37  
38 indicate greater impairment. The Spanish version of the FIQR and has obtained high internal  
39  
40 consistency estimates ( $\alpha = .91 - .95$ ), adequate test-retest reliability indices ( $r = .82$ ), and good  
41  
42 construct validity.<sup>47</sup>  
43  
44  
45  
46

47 The *Depression Anxiety Stress Scales-21* (DASS-21)<sup>48</sup> is a self-report scale developed  
48  
49 to discriminate between features of depression (anhedonia/low positive affect), anxiety  
50  
51 (physical arousal) and stress (psychological tension/agitation) in clinical and non-clinical  
52  
53 samples. The DASS has been validated in patients with FMS.<sup>49</sup> Responders are required to  
54  
55 indicate the presence of a symptom over the previous week. Each item is scored from 0 (“did  
56  
57 not apply to me at all over the last week”) to 3 (“applied to me very much or most of the time  
58  
59  
60

1  
2  
3 over the past week”). There are seven items on each of the three subscales: depression, anxiety,  
4 and stress. Therefore, total scores in each scale can range from 0 to 21. Higher scores indicate  
5 more severe levels of depression, anxiety and stress. The Spanish version showed adequate  
6 internal consistency for depression ( $\alpha = .84$ ), anxiety ( $\alpha = .70$ ) and stress ( $\alpha = .82$ ).<sup>50</sup>  
7  
8  
9

10  
11  
12 The *Multidimensional Inventory of Subjective Cognitive Impairment* (MISCI)<sup>51</sup> is a  
13 10-item self-report measure of subjective cognitive dysfunction (i.e., “fibrofog”) in FMS.  
14 Each item is scored from 1 (“never”) to 5 (“very often”) and the total score ranges from 10 to  
15 50. Lower scores indicate higher cognitive dysfunction. The MISCI showed excellent internal  
16 reliability, low ceiling/floor effects and good convergent validity with a similar measure. The  
17 Spanish version of the MISCI had sound psychometric properties ( $\alpha = .91$  and ICC = .88).<sup>52</sup>  
18  
19  
20  
21  
22  
23  
24  
25

26 The *World Health Organization Disability Assessment Schedule 2.0* (WHODAS  
27 2.0)<sup>53</sup> is a 12-item self-report measure of the level of difficulty experienced taking into  
28 consideration how they usually do the activity. This includes the use of any devices to assist  
29 them and/or the help of a person. In each item, individuals estimate the magnitude of the  
30 disability during the previous 30 days using a five-point scale scored from 1 (none) to 5  
31 (extreme/cannot do). The total score ranges from 0 to 100. Higher scores reflect greater  
32 disability. The 12-item WHODAS 2.0 has sound psychometric properties in patients with  
33 FMS.<sup>54</sup>  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The *Generalized Anxiety Disorder 7-item scale* (GAD-7)<sup>55</sup> is a 7-item self-report  
46 measure of pathological worry. Each item is scored from 0 (“not at all”) to 3 (“nearly every  
47 day”). The total score ranges from 0 to 21, where higher scores reflecting greater anxiety  
48 symptoms. The GAD-7 has sound psychometric properties ( $\alpha = .92$  and ICC = .83) in patients  
49 with FMS in previous studies.<sup>56</sup>  
50  
51  
52  
53  
54  
55

## 56 **Other measures**

57  
58  
59  
60

1  
2  
3 The *ACTION AE* is a *reporting checklist* used to measure safety and benefit-risk of  
4 a clinical trial.<sup>57</sup> The Safety and Benefit-Risk Reporting and Evaluation (SABRRE) Working  
5 Group of the Analgesic, Anaesthetic, and Addiction Clinical Trial Translations, Innovations,  
6 Opportunities, and Networks (ACTION; <http://www.action.org>) public-private partnership  
7 with the FDA developed an adverse events (AE) reporting checklist that will be used in the  
8 present study.  
9  
10  
11  
12  
13  
14  
15  
16

17 The *EuroQoL* (version EQ-5D-5L)<sup>58</sup> is a health-related quality of life questionnaire  
18 that consists of two parts. In the first one, the individual's difficulties concerning mobility,  
19 self-care, pain/discomfort and anxiety/depression are evaluated. In the second part, the  
20 perceived health is assessed by means of a Visual Analogue Scale ranging from 0 to 100. The  
21 EQ-5D-5L scores will be used to calculate the Quality-Adjusted Life Years (QALYs) during  
22 the follow-up period by adjusting the duration of time affected by the health outcome by the  
23 value of the utility.  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 The *Client Service Receipt Inventory* (CSRI)<sup>59</sup> is a self-report tool used to collect  
34 retrospective data on medication consumption and service receipt. Patients are asked to bring  
35 their daily medication prescriptions and information about pain-related drugs (analgesics,  
36 anti-inflammatories, opioids, muscle relaxants, antidepressants, etc.) is recorded. This  
37 includes the name of the drug, the dosage, total number of prescription days and daily dosage  
38 consumed. Concerning service receipt, patients are asked about the total appointments for  
39 accident and emergency services, total number of general inpatient hospital admissions,  
40 number of diagnostic tests administered and total appointments with healthcare professionals  
41 for pain management (family physicians, nurses, social workers, psychologists, psychiatrists,  
42 group psychotherapy and other community healthcare professionals). The CSRI will be  
43 administered on two occasions: at baseline and at 12-month follow-up, both referring to the  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 previous 12 months. Medical records will be checked to verify the accuracy of the collected  
4  
5 data.  
6  
7

8 The *Patient Global Impression of Change* (PGIC) measures meaningful change in  
9  
10 overall status and the *Pain Specific Impression of Change* (PSIC)<sup>60</sup> measures the perception  
11  
12 of pain improvement. The most frequently used scale is a 7-point numerical scale scored from  
13  
14 1= “much better”) to 7= “much worse”).  
15  
16

### 17 **Ecological momentary assessment (EMA)**

18  
19 Pain intensity and other pain-related variables (e.g., depressive-anxious symptoms and  
20  
21 activity level) can fluctuate during the day and across days depending on personal and  
22  
23 environmental factors. Collecting self-reported data prospectively and closer in time to its  
24  
25 occurrence substantially improves the accuracy, reliability and quality of data. EMA has been  
26  
27 successfully performed in patients with a variety of physical and mental problems.<sup>61,62</sup> There  
28  
29 is growing evidence indicating that well-designed smartphone apps can be easy to use and well-  
30  
31 tolerated even in relatively old pain populations, with compliance rates as high as 85%.<sup>61</sup> In  
32  
33 this RCT, we will use the Pain Monitor® (Monitor de Dolor, by its Spanish name) app<sup>63</sup> to  
34  
35 assess a wide range of variables (see items in Table 2) twice a day (once in the morning and  
36  
37 once in the evening, at convenient times along the week) during 120 days. The app and the data  
38  
39 will be stored on different servers with different domain names and connected locally only (the  
40  
41 server containing the data does not have Internet access). According to a recent meta-analysis,<sup>64</sup>  
42  
43 EMA-completion rates are higher among elderly patients compared to younger patients.  
44  
45 Considering that the majority of FMS patients in our study are not expected to be young and  
46  
47 that the EMA item battery does not require a long response time (< 1 min.), it is expected not  
48  
49 to place an excessive burden on participants.  
50  
51  
52  
53  
54  
55

56 Table 2  
57  
58  
59  
60

## Inflammatory biomarkers

After obtaining the blood sample, it will be allowed to coagulate for a minimum of 30 minutes at room temperature. It will then be centrifuged for 10 minutes at 1000g. The resulting serum will be stored at -80° C during the same morning of extraction until it is ready to be analysed. All samples (at T0 and T1) will be analysed in a single analytical batch to reduce inter-assay variability (approx. 15%). The serum levels of IL-1 $\beta$ , sIL-1ra, IL-4, IL-6, sIL-6r, sgp130, CXCL-8, IL-10, IL-17, TNF- $\alpha$ , and high-sensitivity C-reactive protein (hs-CRP) will be evaluated.<sup>29</sup> For the quantification of the cytokines, the Milliplex® reagents from the company MerckMillipore® will be used and analysed using a Luminex® platform. The high sensitivity multiplex kit will be used: Human High Sensitivity T Cell, catalogue number: HSTCMAG28SPMX11, adapted to the aforementioned cytokines. The hs-PCR will be quantified using turbidimetry in an Olympus AU5400 auto-analyser. These biomarkers will only be evaluated at baseline (T0) and 3-months (T1) for the following reasons: (a) there is evidence of significant inflammatory changes at 8 weeks with LDN;<sup>37</sup> (b) this results in lower risk of dropout (vs. evaluating them at 6 or 12 months); (c) conducting at least two measures allows to use the change between baseline and 3-months as a mediator of long-term clinical changes; and (d) budget constraints.

## Neuroimaging

The scans (protocol duration: approximately 30 minutes) will be performed in a Phillips Ingenia 3T MRI scanner with a 32-channel head coil at Hospital Sant Joan de Déu (Esplugues de Llobregat, Spain). To examine cingulate, insular, amygdalar, occipital, angular, parahippocampal, and prefrontal gray matter volume, we will use voxel-based morphometry (VBM). We will also use surface-based morphometry (with FreeSurfer calculation of cortical thickness, surface area, and local gyrification index) for examining cortical abnormalities. Additionally, glutamate, glutamine, myo-inositol, N-acetylaspartate, choline, and creatine



1  
2  
3 (and creatinine ratios) levels will be analysed using magnetic resonance spectroscopy.  
4  
5 Specifically, we will conduct the following processing for the regions of interest according to  
6  
7 the corresponding hypotheses. For VBM, we will apply a bias field correction, tissue  
8  
9 segmentation with SPM12, normalization with DARTEL, modulation, and smoothing. We  
10  
11 will use both unmodulated and modulated grey matter images to convey complementary  
12  
13 volumetric information. We will use FreeSurfer ENIGMA pipelines to perform the VBM. In  
14  
15 addition, we will quantify metabolites concentrations using LCModel (v6.3-1J). We will only  
16  
17 include high-quality spectra, defined as signal-to-noise ratio > 15, Cramer-Rao lower bounds  
18  
19 < 15%, and full width at half maximum of metabolites < .07. The spectroscopy analysis will  
20  
21 account for the effects of cerebrospinal fluid and grey matter within the voxel, and inter-  
22  
23 individual differences in cortical grey matter.  
24  
25  
26  
27

### 28 **Statistical analysis**

29  
30  
31 The main analysis will compare the effect of LDN vs. placebo on the primary outcome  
32  
33 (pain intensity at T1). Data analyses will be performed following an intention-to-treat (ITT)  
34  
35 plan. Then, we will compute analysis of the primary outcome (at T2 and T3) and analysis of  
36  
37 the secondary outcomes at T1, T2 and T3. Linear mixed models will be created using the  
38  
39 restricted maximum likelihood method for the estimation of parameters. The effect sizes will  
40  
41 be calculated according to Cohen's *d*. An interim analysis is planned at T1 once 50% of the  
42  
43 total sample has been evaluated. A 5% significance level will be used in all two-tailed tests,  
44  
45 applying the Benjamini-Hochberg correction for multiple comparisons. Additionally, to make  
46  
47 the findings from our study clinically meaningful, the number needed to treat will be reported.  
48  
49 For this analysis, we will dichotomise participants into responders or non-responders using two  
50  
51 different cut-off criteria in compliance with the IMMPACT recommendations:<sup>45</sup> At least 50%  
52  
53 pain relief over baseline (substantial benefit) or 30% or more pain relief (moderate benefit).  
54  
55 For these analyses, we will use SPSS v26 (IBM Corp, Armonk, NY, USA).  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Regarding EMA, a recent recommended approach is "network analysis". There has been burgeoning interest in conceptualizing chronic pain as a network of interacting symptoms and psychobiological processes.<sup>65</sup> Network analysis will offer us a good chance to quantify and visualize relationships between pain intensity and pain-related variables (e.g., depression, anxiety, fatigue, sleep disturbance). We will estimate temporal networks by means of vector autoregression techniques;<sup>66</sup> These "temporal networks", would indicate potential causality with one or more variables preceding one or more variables in time. Network analysis will be performed with the free statistical software JASP.<sup>67</sup>

In economic evaluation, it is important to calculate the relationship between the costs of each treatment and its consequences in the form of QALYs, an index measure designed to assess both quantity of life (years) and health-related quality of life. A year lived with the maximum quality of life would be transformed into 1 QALY; a year lived with half the maximum quality of life would be transformed into 1/2 QALY. This relative value is called the incremental cost-utility ratio (ICUR) and it expresses the relationship between the costs and the effects of one option compared to another. The QALYs obtained in the 12 months after the treatment onset will be calculated by the area under the curve. The direct costs will be calculated by adding together the costs derived from the medication and the use of the health services. The cost of medications will be calculated by multiplying the price per milligram by the total daily dose consumed (in milligrams) and the number of days that the treatment is received. The cost arising from the use of the health services (primary care, specialist and accident and emergency consultations, and hospital admissions) will be obtained from the clinical electronic records (<http://www.oblikue.com/en/esalud.html>). The indirect costs will be calculated based on the days off work, which will be multiplied by the official minimum wage during the study period. The effect of the treatments will be estimated using ordinary least squares multivariate regression, adjusting for the baseline differences between groups. In order

1  
2  
3 to manage uncertainty in the sampling distribution of the ICUR, non-parametric bootstrapping  
4 will be applied, with 1000 replications in each comparison. Cost-utility analyses will be  
5 conducted with STATA v16.0 (StataCorp, College Station, TX, USA).  
6  
7  
8  
9

### 10 **Patient and public involvement**

11  
12 Patients and the public will not be involved in the design, conduct, reporting, or  
13 dissemination of our research.  
14  
15

### 16 **ETHICS AND DISSEMINATION**

17  
18 All procedures performed in this study will be in accordance with the 1964 Helsinki  
19 declaration and its last amendments (7<sup>th</sup> revision, adopted by the 64<sup>th</sup> World Medical  
20 Association General Assembly, Fortaleza, Brazil). Signed informed consent will be obtained  
21 from all patients once they have been informed of the study procedures, potential risks, and  
22 their right to withdraw at any time from the RCT. The FSJD Ethics Committee Board evaluated  
23 and approved the study protocol in June 2021 (PIC-178-19). Only the principal investigators  
24 (ARS and JVL) will have full access to the final trial dataset. Modifications in the study  
25 protocol will be reported to the FSJD Ethics Committee Board as well as the independent CRO.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Once the RCT is completed, we will publish our results in international peer-reviewed  
39 biomedical journals and present them at national and international conferences. Authorship  
40 will be assigned in accordance with the International Committee of Medical Journal Editors  
41 guidance. In addition, we will send participating patients a short report of our findings. A copy  
42 of the report will also be sent to Institute of Health Carlos III (main funding body). The  
43 principal investigators will organize an end-of-study seminar. The main objective of this  
44 activity will be to share the study findings with stakeholders to discuss how to maximize uptake  
45 of the findings in patient treatment and clinical practice, and to determine future research  
46 directions.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

As far as we know, no RCT has been published about the efficacy, safety, cost-utility, and neurobiological underpinnings of LDN in patients with FMS. This manuscript presents the design and rationale of a randomised, double-blinded, placebo-controlled phase III study, which is a powerful design to assess the efficacy of LDN. We have decided to administer 4.5 mg/day of LDN in this RCT because this dose seems to provide an optimal balance between significant analgesic efficacy and minimal side effects (nausea, sleep disturbance, nightmares, etc.) according to a recent study.<sup>68</sup>

Our findings using this design in conjunction with those that will be obtained in another ongoing RCT that is being carried out in Denmark (The FINAL study)<sup>69</sup> may facilitate the approval of the first drug indicated for the treatment of FMS in Europe. The FINAL study is an ongoing single-centre, randomised, double-blinded, placebo-controlled trial that is being carried out in Odense (Denmark). A total of 100 women between 18–64 years-old with FMS will take either LDN or placebo for three months. Besides self-report measures, Danish researchers will also examine the levels of pro- and anti-inflammatory cytokines. If our respective findings strongly differ in efficacy or safety, we might analyse which factors can account for the divergence and plan a multi-country confirmatory trial with an agreed design and methodology. As pointed out by Kim and Fishman<sup>70</sup>, a common problem with a generic, compounded medication is the lack of commercial support for research. To begin studies such as INNOVA or FINAL, it is crucial to have the synergistic support from public funding bodies, private entities, and commercial companies. This has been the case in the present study, with different public and private organizations providing economic and logistic support.

The inclusion of brain and blood immune biomarkers will allow us to determine whether LDN modulates neuro-inflammatory processes involving inflammatory cells such as glial cells. These markers will also allow us to explore the “hormetic” effects of the drug, that

1  
2  
3 is, if a low dose of an antagonist (naltrexone) may paradoxically act as an agonist of the  
4  
5 endogenous opiate system. As explained above, it is posited that LDN mainly acts as an  
6  
7 immunomodulatory drug via blockade of TLR-4, which provides a therapeutic pathway to  
8  
9 reduce activation of the inflammatory cascade and the nociceptive system.<sup>71</sup> In a recent pilot  
10  
11 study<sup>72</sup>, patients with opioid induced hyperalgesia and patients with FMS were treated with  
12  
13 LDN for 3 months. Via different mechanisms of action, LDN improved pain tolerance  
14  
15 (measured with the cold pressor test) in both groups of patients, being the effect even stronger  
16  
17 in those participants with opioid induced hyperalgesia. According to the authors, the  
18  
19 mechanism of action that would explain the beneficial effects of LDN for FMS may be transient  
20  
21 blockade of the opioid growth factor receptor.  
22  
23  
24  
25

26  
27 Obtaining empirical evidence for cost-utility of treatments or interventions is required  
28  
29 by the Ministry of Health in Spain for reimbursement. In Spain, a threshold of €22,000–25,000  
30  
31 per QALY gained is found to be consistent with decisions of adopting new technologies by the  
32  
33 National Health Service.<sup>73</sup> To our knowledge, there is an absence of economic evaluations for  
34  
35 LDN; therefore, an important feature of the present study is the cost-utility assessment of the  
36  
37 drug.  
38  
39

40  
41 FMS remains a chronic, debilitating, and difficult to manage condition for many  
42  
43 individuals around the world. After three decades of intensive research, the clinical benefits of  
44  
45 pharmacological treatments remain unclear and limited. This study will evaluate the analgesic  
46  
47 efficacy, safety, and cost-utility of LDN using a rigorous and powered design. If efficacious  
48  
49 and cost-effective, LDN might be the first drug approved for FMS in Europe.  
50

### 51 **Trial status**

52  
53  
54 This study is currently in the recruitment phase. The first patient will be enrolled in  
55  
56 January 2022, and the study is expected to end in August 2024.  
57

### 58 **Confidentially**

1  
2  
3 Personal data will be stored in accordance with the Spanish regulation guidelines for  
4 clinical research. Participants will be allocated a unique identification (ID) number at entry.  
5  
6 The master list linking participant personal information and ID number will be maintained in  
7  
8 a password-protected hard drive at the PSSJD. Data will be stored for 10 years after study  
9  
10 completion.  
11  
12  
13

### 14 **Contributors**

15  
16 JVL, ARS, and AFS conceived the study and revised the manuscript. JVL drafted the  
17 manuscript. ACC, JPSM, HHN, XB, CSR, AGP, JM, JM, FDA, MM, JWY, AFS and ARS  
18 provided feedback on the manuscript, and all authors reviewed and approved the final version  
19  
20 of the manuscript.  
21  
22  
23  
24

### 25 **Funding**

26  
27 This study has been funded by the Institute of Health Carlos III (ISCIII; ICI20/00080;  
28  
29 CPII19/00003) and has been co-financed with European Union ERDF funds. JPS-M has a PFIS  
30  
31 predoctoral contract from the ISCIII (FI20/00034). AC-C has a FI predoctoral contract from  
32  
33 AGAUR (FI\_B/00216). AF-S acknowledges the funding from the Serra Húnter program  
34  
35 (UAB-LE-8015). The ISCIII did not have any role in the analysis and interpretation of data, in  
36  
37 the writing of the manuscript, or in the decision to submit the paper for publication.  
38  
39  
40  
41

### 42 **Competing interests**

43  
44 None declared.  
45  
46

### 47 **Patient consent for publication**

48  
49 Not required.  
50  
51

### 52 **Provenance and peer review**

53  
54 Not commissioned; externally peer reviewed.  
55  
56  
57  
58  
59  
60

**REFERENCES**

1. Häuser W, Ablin J, Fitzcharles MA, *et al.* Fibromyalgia. *Nat Rev Dis Primers* 2015;1:15022.
2. Fietta P, Fietta P, Manganeli P. Fibromyalgia and psychiatric disorders. *Acta Biomed* 2007;78:88-95.
3. Queiroz LP. Worldwide epidemiology of fibromyalgia. *Curr Pain Headache Rep* 2013;17:356.
4. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. *Curr Opin Investig Drugs* 2010;11:16-8.
5. Nüesch E, Häuser W, Bernardy K, *et al.* Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: Network meta-analysis. *Ann Rheum Dis* 2013;72:955-62.
6. Thieme K, Mathys M, Turk DC, *et al.* Evidenced-based guidelines on the treatment of fibromyalgia patients: Are they consistent and if not, why not? Have effective psychological treatments been overlooked? *J Pain* 2017;18:747-56.
7. Cagnie B, Coppieters I, Denecker S, *et al.* Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. *Semin Arthritis Rheum* 2014;44:68-75.
8. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* 2011;152:S2-15.
9. Napadow V, LaCount L, Park K, *et al.* Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. *Arthritis Rheum* 2010;62:2545-55
10. Jensen KB, Berna C, Loggia ML, *et al.* The use of functional neuroimaging to evaluate psychological and other non-pharmacological treatments for clinical pain. *Neurosci Lett* 2012;520:156-64.

- 1  
2  
3 11. Zunhammer M, Schweizer LM, Witte V, *et al.* Combined glutamate and glutamine  
4 levels in pain-processing brain regions are associated with individual pain sensitivity. *Pain*  
5 2016;157:2248-56.  
6  
7
- 8  
9  
10 12. Pyke TL, Osmotherly PG, Baines S. Measuring glutamate levels in the brains of  
11 fibromyalgia patients and a potential role for glutamate in the pathophysiology of  
12 fibromyalgia symptoms. *Clin J Pain* 2017;33:944-54.  
13  
14
- 15 13. Napadow V, Harris RE. What has functional connectivity and chemical neuroimaging  
16 in fibromyalgia taught us about the mechanisms and management of centralized pain?  
17 *Arthritis Res Ther*, 2014;16:425.  
18  
19
- 20 14. Fayed N, Andres E, Rojas G, *et al.* Brain dysfunction in fibromyalgia and somatization  
21 disorder using proton magnetic resonance spectroscopy: a controlled study. *Acta Psychiatr*  
22 *Scand* 2012;126:115-25.  
23  
24
- 25 15. Fayed N, Garcia-Campayo J, Magallón R, *et al.* Localized 1H-NMR spectroscopy in  
26 patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine,  
27 inositol, choline, and N-acetylaspartate. *Arthritis Res Ther* 2010;12:R134.  
28  
29
- 30 16. Harris RE, Sundgren PC, Craig AD, *et al.* Elevated insular glutamate in fibromyalgia  
31 is associated with experimental pain. *Arthritis Rheum* 2009;60:3146-52.  
32  
33
- 34 17. Feraco P, Bacci A, Pedrabissi F, *et al.* Metabolic abnormalities in pain-processing  
35 regions of patients with fibromyalgia: a 3T MR spectroscopy study. *Am J Neurorad*  
36 2011;32:1585-90  
37  
38
- 39 18. Harris RE, Napadow V, Huggins JP, *et al.* Pregabalin rectifies aberrant brain chemistry,  
40 connectivity, and functional response in chronic pain patients. *Anesthesiology*  
41 2013;119:1453-64.  
42  
43
- 44 19. Murga I, Guillen V, Lafuente JV. Cerebral magnetic resonance changes associated with  
45 fibromyalgia syndrome. *Med Clin* 2017;148(11):511-6  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med* 2004;140:441-51.
21. Ji RR, Berta T, Nedergaard M, *et al.* Glia and pain: is chronic pain a gliopathy? *Pain* 2013;154:S10-S28.
22. Lynch MA. The multifaceted profile of activated microglia. *Mol Neurobiol* 2009;40:139-56.
23. Watkins LR, Hutchinson MR, Ledebor A, *et al.* Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. *Brain Behav Immun* 2007;21:131-46
24. Kettenmann H, Hanisch UK, Noda M, *et al.* Physiology of microglia. *Physiol Rev* 2011;91:461-553.
25. Dantzer R. Cytokine, sickness behavior, and depression. *Immunol Allergy Clin North Am* 2009;29:247-64.
26. Haroon E, Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. *Neuropsychopharmacol* 2017;42:193-215.
27. Albrecht DS, Forsberg A, Sandström A, *et al.* Brain glial activation in fibromyalgia -A multi-site positron emission tomography investigation. *Brain Behav Immun* 2019;75:72-83.
28. Niraula A, Sheridan JF, Godbout JP. Microglia priming with aging and stress. *Neuropsychopharmacol.* 2017;42:318.
29. Andrés-Rodríguez L, Borràs X, Feliu-Soler A, *et al.* Peripheral immune aberrations in fibromyalgia: A systematic review, meta-analysis and meta-regression. *Brain Behav Immun* 2020;87:881-9.
30. Bäckryd E, Tanum L, Lind AL, *et al.* Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. *J Pain Res* 2017;10:515.

- 1  
2  
3 31. Kiguchi N, Kobayashi Y, Kishioka S. Chemokines and cytokines in neuroinflammation  
4 leading to neuropathic pain. *Curr Opin Pharmacol* 2012;12:55 -61.  
5  
6
- 7 32. Miller AH, Haroon E, Raison CL, *et al.* Cytokine targets in the brain: impact on  
8 neurotransmitters and neurocircuits. *Depress Anxiety* 2013;30:297-306.  
9
- 10 33. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel  
11 anti-inflammatory treatment for chronic pain. *Clin Rheumatol* 2014;33:451-9.  
12
- 13 34. Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in  
14 the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia,  
15 Crohn's disease, and other chronic pain disorders. *Pharmacotherapy* 2018;38(3):382-9.  
16
- 17 35. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: A  
18 pilot study. *Pain Med* 2009;10(4):663-72.  
19
- 20 36. Younger J, Noor N, McCue R, *et al.* Low-dose naltrexone for the treatment of  
21 fibromyalgia: findings of a small, randomized, double-blind, placebocontrolled,  
22 counterbalanced, crossover trial assessing daily pain levels. *Arthritis Rheum.* 2013;65:529-  
23 38.  
24
- 25 37. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-  
26 dose naltrexone for fibromyalgia. *Biomedicines.* 2017;5:16.  
27
- 28 38. Chan AW, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard  
29 protocol items for clinical trials. *Ann Intern Med* 2013;158:200-7.  
30
- 31 39. Schulz KF, Altman DG, Moher D, *et al.* CONSORT 2010 Statement: updated  
32 guidelines for reporting parallel group randomized trials. *BMJ* 2010;340:c332.  
33
- 34 40. Husereau D, Drummond M, Petrou S, *et al.* Consolidated Health Economic Evaluation  
35 Reporting Standards (CHEERS) statement. *BMC Med* 2013;11:80.  
36
- 37 41. Fayed N, Oliván-Blázquez B, Herrera-Mercadal P, *et al.* Changes in metabolites after  
38 treatment with memantine in fibromyalgia. A double blind randomized controlled trial with  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 magnetic resonance spectroscopy with a 6 month follow up. *CNS Neurosci Ther*  
4 2014;20:999-1007.  
5  
6  
7  
8 42. Gálvez-Sánchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia:  
9 Critical Review and Future Perspectives. *J Clin Med* 2020;9(4):1219.  
10  
11  
12 43. Häuser W, Jung E, Erbslöh-Möller B, *et al.* Validation of the fibromyalgia survey  
13 questionnaire within a cross-sectional survey. *PLoS One* 2012;7:e37504.  
14  
15  
16 44. Carrillo-de-la-Peña MT, Triñanes Y, González-Villar A, *et al.* Convergence between  
17 the 1990 and 2010 ACR diagnostic criteria and validation of the Spanish version of the  
18 Fibromyalgia Survey Questionnaire (FSQ). *Rheumatol Int* 2015;35:141–151.  
19  
20  
21  
22 45. Dworkin RH, Turk DC, Wyrwich KW, *et al.* Interpreting the clinical importance of  
23 treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. *J Pain*  
24 2008;9(2):105-21.  
25  
26  
27  
28  
29  
30 46. Bennett RM, Friend R, Jones KD, *et al.* The Revised Fibromyalgia Impact  
31 Questionnaire (FIQR): Validation and psychometric properties. *Arthritis Res Ther*  
32 2009;11:R120.  
33  
34  
35  
36  
37 47. Luciano JV, Aguado J, Serrano-Blanco A, *et al.* Dimensionality, reliability, and validity  
38 of the revised fibromyalgia impact questionnaire in two spanish samples. *Arthritis Care Res*  
39 2013;65:1682–9.  
40  
41  
42  
43  
44 48. Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of  
45 the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety  
46 Inventories. *Behav Res Ther* 1995;33:335-43.  
47  
48  
49  
50 49. Alok R., Das SK., Agarwal GG, *et al.* Relationship of severity of depression, anxiety  
51 and stress with severity of fibromyalgia. *Clin Exp Rheumatol* 2011;29(6 Suppl 69):S70-2.  
52  
53  
54  
55 50. Bados A, Solanas A, Andrés R. Psychometric properties of the Spanish version of  
56 Depression, Anxiety and Stress Scales (DASS). *Psicothema* 2005;17:679-83.  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
51. Kratz AL, Schilling SG, Goesling J, *et al.* Development and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia. *J Pain* 2015;16:527–36.
  52. Feliu-Soler A, Pérez-Aranda A, Andrés-Rodríguez L, *et al.* Digging into the construct of fibrofog: Psychometric properties of the Spanish version of the Multidimensional Inventory of Subjective Cognitive Impairment in patients with fibromyalgia. *J Appl Biobehav Res* 2018:e12134.
  53. Vázquez-Barquero JL, Vázquez Bourgón E, Herrera Castanedo S, *et al.* Spanish version of the new World Health Organization Disability Assessment Schedule II (WHO-DAS-II): Initial phase of development and pilot study. Cantabria disability work group. *Actas Esp Psiquiatr* 2000;28:77-87.
  54. Smedema SM, Yaghmaian RA, Ruiz D, *et al.* Psychometric validation of the world health organization disability assessment schedule 2.0-12-item version in persons with fibromyalgia syndrome. *J Rehabil* 2016;82(3):28-35
  55. Spitzer RL, Kroenke K, Williams JB, *et al.* A brief measure for assessing generalized anxiety disorder: The GAD-7. *Arch Intern Med* 2006;166(10):1092-7
  56. Robinson RL, Kroenke K, Williams, DA, *et al.* Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the REFLECTIONS study. *Pain Med.* 2013;14(9):1400-15.
  57. Smith SM, Wang AT, Katz NP, *et al.* Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTION systematic review and recommendations. *Pain* 2013;154(7):997-1008.
  58. Herdman M, Gudex C, Lloyd A, *et al.* Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
  59. Vázquez-Barquero JL, Gaité L, Cuesta MJ, *et al.* Spanish version of the CSRI: a mental health cost evaluation interview. *Arch Neurobiol (Madr)* 1997;60:171-84.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
60. Scott W, McCracken LM. Patients' impression of change following treatment for chronic pain: global, specific, a single dimension, or many? *J Pain* 2015;16:518–26.
61. May M, Junghaenel DU, Ono M, *et al.* Ecological momentary assessment methodology in chronic pain research: A systematic review. *J Pain* 2018;19:699-716.
62. Colombo D., Fernández-Álvarez J, Patané, A, *et al.* Current state and future directions of technology-based ecological momentary assessment and intervention for major depressive disorder: a systematic review. *J Clin Med* 2019;8(4):465.
63. Suso-Ribera C, Castilla D, Zaragoza I, *et al.* Validity, reliability, feasibility, and usefulness of Pain Monitor: A multidimensional smartphone app for daily monitoring of adults with heterogeneous chronic pain. *Clin J Pain* 2018;34:900-8.
64. Ono M, Schneider S, Junghaenel DU, *et al.* What affects the completion of ecological momentary assessments in chronic pain research? An individual patient data meta-analysis. *J Med Internet Res* 2019;21(2):e11398
65. Penedo JMG, Rubel JA, Blättler L, *et al.* The complex interplay of pain, depression, and anxiety symptoms in patients with chronic pain: A network approach. *Clin J Pain* 2020;36:249-59
66. Bringmann LF, Vissers N, Wichers M, *et al.* A network approach to psychopathology: new insights into clinical longitudinal data. *PloS One* 2013;8(4)
67. Love J, Selker R, Marsman M, *et al.* JASP: Graphical statistical software for common statistical designs. *J Stat Softw* 2019;88(2):1-17.
68. Bruun-Plesner KD, Blichfeldt-Eckhardt MR, Vaegter HB, *et al.* Low-dose naltrexone for the treatment of fibromyalgia: Investigation of dose–response relationships. *Pain Med* 2020;21(10):2253-61.

- 1  
2  
3 69. Bruun-Plesner KD, Amris K, Vaegter, HB, *et al.* Low dose naltrexone for the treatment  
4 of fibromyalgia: Protocol for a double-blind, randomized, placebo-controlled trial, 08 April  
5 2021, PREPRINT (Version 1) available at *Research Square*.  
6  
7  
8  
9  
10 70. Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic  
11 review. *Curr Pain Headache Rep* 2020;24(10):1-8  
12  
13  
14 71. Hatfield E, Phillips K, Swidan S, *et al.* Use of low-dose naltrexone in the management  
15 of chronic pain conditions: A systematic review. *J Am Dent Assoc* 2020;151(12):891-902.  
16  
17  
18 72. Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose  
19 naltrexone on opioid induced hyperalgesia and fibromyalgia. *Front Psychiatry*. 2021; 12:  
20 593842.  
21  
22  
23  
24  
25 73. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a  
26 cost-effectiveness threshold for the Spanish NHS. *Health Econ* 2018;27(4):746-61.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Time points for data collection.

Measures	T0 (baseline)	T1 (3-m)	T2 (6-m)	T3 (12-m)
<i>Sociodemographic, clinical, and screening measures</i>				
Sociodemographic data	X			
Clinical data (years of evolution, comorbidities, etc.)	X			
FSDC screening and secondary outcome measure (fibromyalginess)	X	X	X	X
<i>Primary outcome measure</i>				
NRS (pain intensity)	X	X	X	X
<i>Secondary outcome measures</i>				
FIQR (functional impairment)	X	X	X	X
DASS-21 (anxiety, depression, and stress)	X	X	X	X
MISCI (subjective cognitive impairment)	X	X	X	X
WHODAS 2.0 (disability)	X	X	X	X
GAD-7 (general anxiety / worry)	X	X	X	X
<i>Other measures</i>				
EQ-5D-5L (quality of life)	X			X
CSRI (medication consumption and service receipt)	X			X
PGIC and PSIC (impression of change)		X	X	X
ACTTION checklist (adverse events throughout the trial)	X	X	X	X
Pain Monitor® app (EMA)	X	X		
<b>Physiological variables</b>				
Immune biomarkers	X	X		
Neuroimaging	X	X		

ACTTION checklist: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks; CSRI: Client Service Receipt Inventory; DASS-21: Depression Anxiety Stress Scales-21; EQ-5D-5L: EuroQoL; EMA: Ecological Momentary Assessment; FIQR: Fibromyalgia Impact Questionnaire Revised; FSDC: Fibromyalgia Survey Diagnostic Criteria; GAD-7: Generalized Anxiety Disorder 7-item scale; NRS: Numerical Pain Rating Scale; PGIC and PSIC= Patient Global Impression of Change and Pain Specific Impression of Change; WHODAS 2.0: 12-item interviewer administered version of the World Health Organization Disability Assessment Schedule 2.0

**Table 2.** List of items administered via Pain Monitor® app.

Items	Morning	Evening
Pain intensity	X	X
Fatigue	X	X
Perceived control over pain	X	X
Depression	X	X
Anxiety	X	X
Stress	X	X
Sleep disturbance	X	
Activity level		X
Interference with leisure activities		X
Interference with work-related activities		X
Adverse effects		X
Rescue medications		X

The Pain Monitor app automatically informs patients when to respond (by default, at 11 AM and 7 PM) using a push notification system, but patients can respond with a margin of 2 hours from given times. Collected data are stored on a secure server at the Jaume I University, Spain.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1.** Flowchart of the INNOVA study based on the CONSORT guidelines.

For peer review only




Figure 1. Flowchart of the INNOVA study based on the CONSORT guidelines.

190x275mm (96 x 96 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item N°	Description	Pages
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
Trial registration	2b	All items from the World Health Organization Trial Registration Data Set	n.a
	3	Date and version identifier	n.a
Protocol version	3	Date and version identifier	n.a
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1,2,23
	5b	Name and contact information for the trial sponsor	2
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	23
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	5-8
	6b	Explanation for choice of comparators	8
Objectives	7	Specific objectives or hypotheses	8

1			
2		Description of trial design including type of trial (eg, parallel	
3		group, crossover, factorial, single group), allocation ratio, and	
4	Trial design	8 framework (eg, superiority, equivalence, noninferiority,	8
5		exploratory)	
6			
7			
8		<b>Methods: Participants, interventions, and outcomes</b>	
9			
10		Description of study settings (eg, community clinic, academic	
11	Study setting	9 hospital) and list of countries where data will be collected.	10
12		Reference to where list of study sites can be obtained	
13			
14		Inclusion and exclusion criteria for participants. If applicable,	
15	Eligibility criteria	10 eligibility criteria for study centres and individuals who will	9
16		perform the interventions (eg, surgeons, psychotherapists)	
17			
18			
19		11a Interventions for each group with sufficient detail to allow	11
20		replication, including how and when they will be administered	
21			
22		Criteria for discontinuing or modifying allocated interventions for	
23		11b a given trial participant (eg, drug dose change in response to	12
24		harms, participant request, or improving/worsening disease)	
25	Interventions		
26		Strategies to improve adherence to intervention protocols, and	
27		11c any procedures for monitoring adherence (eg, drug tablet return,	10
28		laboratory tests)	
29			
30		11d Relevant concomitant care and interventions that are permitted	11
31		or prohibited during the trial	
32			
33			
34		Primary, secondary, and other outcomes, including the specific	
35		measurement variable (eg, systolic blood pressure), analysis	12-18
36		metric (eg, change from baseline, final value, time to event),	Table 1
37	Outcomes	12 method of aggregation (eg, median, proportion), and time point	Table 2
38		for each outcome. Explanation of the clinical relevance of	
39		chosen efficacy and harm outcomes is strongly recommended	
40			
41			
42		Time schedule of enrolment, interventions (including any run-ins	
43	Participant	13 and washouts), assessments, and visits for participants. A	Fig. 1
44	timeline	schematic diagram is highly recommended (see Figure)	
45			
46		Estimated number of participants needed to achieve study	
47		objectives and how it was determined, including clinical and	9
48	Sample size	14 statistical assumptions supporting any sample size calculations	
49			
50			
51		Strategies for achieving adequate participant enrolment to reach	
52	Recruitment	15 target sample size	10
53			

**Methods: Assignment of interventions (for controlled trials)**

Allocation:

1				
2			Method of generating the allocation sequence (eg, computer-	
3			generated random numbers), and list of any factors for	
4	Sequence		stratification. To reduce predictability of a random sequence,	
5	generation	16a	details of any planned restriction (eg, blocking) should be	10
6			provided in a separate document that is unavailable to those	
7			who enrol participants or assign interventions	
8				
9				
10	Allocation		Mechanism of implementing the allocation sequence (eg, central	
11	concealment		telephone; sequentially numbered, opaque, sealed envelopes),	
12	mechanism	16b	describing any steps to conceal the sequence until interventions	10
13			are assigned	
14				
15	Implementation	16c	Who will generate the allocation sequence, who will enrol	10
16			participants, and who will assign participants to interventions	
17				
18				
19			Who will be blinded after assignment to interventions (eg, trial	
20		17a	participants, care providers, outcome assessors, data analysts),	10-11
21	Blinding (masking)		and how	
22				
23			If blinded, circumstances under which unblinding is permissible,	
24		17b	and procedure for revealing a participant's allocated intervention	11
25			during the trial	
26				
27				
28	<b>Methods: Data collection, management, and analysis</b>			
29				
30			Plans for assessment and collection of outcome, baseline, and	
31			other trial data, including any related processes to promote data	
32			quality (eg, duplicate measurements, training of assessors) and	
33		18a	a description of study instruments (eg, questionnaires,	12-18
34	Data collection		laboratory tests) along with their reliability and validity, if known.	
35	methods		Reference to where data collection forms can be found, if not in	
36			the protocol	
37				
38				
39			Plans to promote participant retention and complete follow-up,	
40		18b	including list of any outcome data to be collected for participants	10
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	19	Plans for data entry, coding, security, and storage, including any	11
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of	
47			data management procedures can be found, if not in the	
48			protocol	
49				
50				
51			Statistical methods for analysing primary and secondary	
52	Statistical	20a	outcomes. Reference to where other details of the statistical	18-19
53	methods		analysis plan can be found, if not in the protocol	
54				
55		20b	Methods for any additional analyses (eg, subgroup and adjusted	19-20
56			analyses)	
57				
58				
59				
60				

		Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	18
		<b>Methods: Monitoring</b>	
Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	18
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	11
		<b>Ethics and dissemination</b>	
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	21
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	21
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n.a
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	23
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	24
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	21

1				
2	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for	n.a
3	trial care		compensation to those who suffer harm from trial participation	
4				
5			Plans for investigators and sponsor to communicate trial results	
6			to participants, healthcare professionals, the public, and other	
7		31a	relevant groups (eg, via publication, reporting in results	21
8			databases, or other data sharing arrangements), including any	
9			publication restrictions	
10	Dissemination			
11	policy			
12		31b	Authorship eligibility guidelines and any intended use of	24
13			professional writers	
14				
15		31c	Plans, if any, for granting public access to the full protocol,	8
16			participant-level dataset, and statistical code	
17				
18				
19	<b>Appendices</b>			
20	Informed consent	32	Model consent form and other related documentation given to	Attached
21	materials		participants and authorised surrogates	
22				
23			Plans for collection, laboratory evaluation, and storage of	
24	Biological	33	biological specimens for genetic or molecular analysis in the	17
25	specimens		current trial and for future use in ancillary studies, if applicable	
26				
27				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.